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Abstract——GABAA receptors are themajor inhibitory
transmitter receptors in the brain. They are ligand-gated
chloridechannelsand thesiteofactionofbenzodiazepines,
barbiturates, neuroactive steroids, anesthetics, and
convulsants. GABAA receptors are composed of five
subunits that can belong to different subunit classes.
The existence of 19 homologous subunits and their
distinct regional, cellular, and subcellular distribution
gives rise to a large number of GABAA receptor subtypes
with distinct pharmacology, which modulate different
functions of the brain. A variety of compounds have been
identified that were claimed to modulate selectively
individual GABAA receptor subtypes. However, many
of these compounds have only incompletely been
investigated or, in addition to a preferential modulation
of a receptor subtype, also modulate other subtypes at
similar concentrations. Although their differential
efficacy at distinct receptor subtypes reduced side
effects in behavioral experiments in rodents, the exact
receptor subtypes mediating their behavioral effects
cannot be unequivocally delineated. In addition, the
discrepant in vivo effects of some of these compounds
in rodents and man raised doubts on the applicability
of the concept of receptor subtype selectivity as a guide
for the development of clinically useful drugs. Here, we
provide an up-to-date review on the currently available
GABAA receptor subtype-selective ligands. We present
data on their actual activity atGABAA receptor subtypes,
discuss the translational aspect of subtype-selective
drugs, and make proposals for the future development
of ligands with better anxioselectivity in humans.
Finally, we discuss possible ways to strengthen the
conclusions of behavioral studies with the currently
available drugs.
I. Introduction
A. g-Aminobutyric Acid Type A Receptors and
Their Heterogeneity
g-Aminobutyric acid (GABA) is the major inhibitory
transmitter of the central nervous system and exerts its
action via two types of receptors, GABAA and GABAB
receptors. Whereas GABAB receptors are metabotropic
receptors that activate inwardly rectifying K+ channels
and/or inhibit high voltage-activated Ca2+ channels
(Bettler et al., 2004), GABAA receptors belong to the
Cys-loop family of pentameric ligand-gated ion chan-
nels that includes the nicotinic acetylcholine-, serotonin
type 3- , and strychnine-sensitive glycine receptors (Galzi
and Changeux, 1994; Olsen and Sieghart, 2008), a
Zn2+-activated ion channel (Davies et al., 2003), and
an invertebrate glutamate-gated chloride channel (Hibbs
andGouaux, 2011). GABAA receptors are anion-selective
channels, and increased chloride permeability generally
reduces neuronal excitability. But these receptors also
can conduct other anions with variable permeability
ratios relative to chloride. For instance, HCO3
2 flux
could be physiologically relevant under certain condi-
tions (Kaila et al., 1997; Olsen and Sieghart, 2008).
Twenty distinct GABAA receptor subunit genes (6a, 4b,
3g, d, «, p, u, 3r) have been identified in the vertebrate
nervous system, including a putative b4 subunit gene that
originally was identified in chicken (Bateson et al., 1991),
but also has been demonstrated in humans (Levin et al.,
1996; Berezhnoy et al., 2007). These genes as well as
several alternatively spliced isoforms of the respective
subunits, for instance g2L and g2S, give rise to a
possible enormous heterogeneity of GABAA receptor
subtypes (Barnard et al., 1998; Berezhnoy et al., 2007;
Olsen and Sieghart, 2008). Recently, the extent of hetero-
geneity has been extensively discussed together with
criteria for theunequivocal identification of nativeGABAA
receptor subtypes. So far, no sufficient new information
has been accumulated that would justify the addition of
a new member to the list of 26 GABAA receptor
subtypes “identified” or “existing with a certain proba-
bility” (Olsen andSieghart, 2008). Themajority ofGABAA
receptors is composed of two a, two b, and one g subunits
(abg receptors, for receptor nomenclature, see Alexander
et al., 2015; Olsen and Sieghart, 2008). In these recep-
tors, alternating a and b subunits are connected by a g
subunit (Tretter et al., 1997). Depending on the subunit
composition and arrangement, these receptors exhibit
different pharmacology, anddue to their distinct regional
and cellular distribution (Wisden et al., 1992; Fritschy
and Mohler, 1995; Pirker et al., 2000; Hörtnagl et al.,
2013) each receptor subtype also contributes to the
modulation of distinct functions of the brain (Sieghart,
1995; Olsen and Sieghart, 2008). Whereas GABAA recep-
tors composed ofa1bg2,a2bg2,a3bg2 are predominantly
located synaptically and contribute to phasic inhibition,
receptors composed of a4bg2, a5bg2, a6bg2, or ab«
subunits are partially located extrasynaptically and
therefore, contribute to both phasic and tonic inhibition
of neurons (Wagner et al., 2005; Glykys andMody, 2007a;
Belujon et al., 2009;Chen et al., 2017). In contrast,GABAA
receptors composed of ab or abd subunits seem to be
exclusively located extrasynaptically and hence only exert
a tonic inhibition of neurons (Brickley and Mody, 2012).
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In addition, at least some GABAA receptor subtypes
not only can be modulated by GABA but also exhibit
some spontaneous gating in the absence ofGABAand thus
also contribute to tonic inhibition (Wlodarczyk et al., 2013).
These include a6b2g2 (Knoflach et al., 1996), a6b2d
(Hadley and Amin, 2007); a4b3g2 and a4b3d (Tang et al.,
2010); a4b1d, a4b2d, a6b1d, a6b3d, a1b3d (Karim et al.,
2012b); or receptors containing an « subunit (Neelands
et al., 1999; Wagner et al., 2005). Furthermore, rat or
murine homo-oligomeric b1 receptors exhibit spontane-
ous gating that could be inhibited by picrotoxin (Sigel
et al., 1989; Krishek et al., 1996) and modulated by
pentobarbital and propofol (Krishek et al., 1996). These
receptors, however, were insensitive to GABA. In contrast,
bovine (Krishek et al., 1996) or humanb1 receptors (Sanna
et al., 1995) that also exhibit spontaneous gating were
GABA sensitive. GABA sensitivity of homo-oligomeric
b1 receptors thus seems to be species dependent. Homo-
oligomeric b3 receptors are also spontaneously open ion
channels that are insensitive to GABA (Cestari et al.,
1996; Wooltorton et al., 1997) and can be modulated by
various allosteric modulators, such as pentobarbital,
etomidate, alphaxalone, propofol, and chlormethiazole
(Slany et al., 1995;Wooltorton et al., 1997). Interestingly,
however, these receptors could be further activated by
histamine (Saras et al., 2008; Seeger et al., 2012). Homo-
oligomeric b3 receptors are thus not GABA-gated but
histamine-gated channels (Saras et al., 2008; Hoerbelt
et al., 2016). In contrast to the receptors mentioned
above and composed of abg2 or abd subunits that were
classified as “identified in the nervous system,” recep-
tors containing « subunits were classified as “tenta-
tively occurring in the brain” (Olsen and Sieghart, 2008).
Homo-oligomeric b1- or b3-containing receptors so far
have not been demonstrated in the brain due to a lack
of specific tools that could identify them among a variety
of hetero-oligomeric ab, abg, or abd receptors. However,
especially homo-oligomeric b3 receptors are easily formed
in recombinant expression systems (Slany et al., 1995;
Cestari et al., 1996;Miller andAricescu, 2014) and there is
no reason to believe that they cannot also be formed in the
nervous system (Hoerbelt et al., 2016). In any case, drugs
that can modulate spontaneously open receptors will also
modulate tonic inhibition.
It has to be kept in mind, however, that depending on
the chloride concentration in the inside of neurons, that
is enhanced by the Na+-K+-2Cl2 cotransporter NKCC1
and reduced by the K+-Cl2 cotransporter KCC2, opening
of theGABAA receptor associatedCl
2 channel can elicit a
depolarization and hyperpolarization, respectively. Dur-
ing early development of the nervous system NKCC1
predominates, resulting in a high Cl2 concentration
in the inside of neurons and thus in a Cl2 efflux on
activation of GABAA receptors (Ben-Ari et al., 2012;
Kaila et al., 2014). At this time, GABA is an excitatory
transmitter. During the establishment of the excit-
atory glutamate system in the brain the expression of
KCC2 increases, the Cl2 concentration in the inside of
neurons decreases and activation of GABAA receptors
causes Cl2 influx and thus a hyperpolarization. In the
adult brain, activation of GABAA receptors in most
cases results in a hyperpolarization, and thus GABAA
receptors become the major inhibitory transmitter re-
ceptors in the nervous system. But even then, depolariz-
ing actions of GABA can also occur in some neurons or
even in individual compartments of neurons, depending
on the subcellular localization of NKCC1 and KCC2 as
well as on the intracellular distribution of large imper-
meable anions that are predicted to cause a discrete
balance of chloride ions (Astorga et al., 2015; Knoflach
et al., 2016).
B. g-Aminobutyric Acid Type A Receptor Structure
and Pharmacology
GABAA receptors are the site of action of a variety
of pharmacologically and clinically important drugs,
such as benzodiazepines, barbiturates, anesthetics,
neuroactive steroids, and convulsants (Sieghart, 1995;
Berezhnoy et al., 2007). Whereas GABA exerts its
channel opening effects via two binding sites located
at the two extracellular interfaces of b and a subunits
(b+a2 interfaces), (Smith and Olsen, 1995), benzodiaze-
pines bind to the homologous interface of an a and a g
subunit (a+g2 interface) (Sigel and Buhr, 1997; Ernst
et al., 2003). Ligands acting via the benzodiazepine
binding site cannot directly open the GABAA receptor-
associated chloride channel, but only allosterically
enhance (positive allosteric modulators) or reduce (neg-
ative allosteric modulators) GABA-induced currents. A
third group of benzodiazepine site ligands does not
significantly change the conformation of GABAA recep-
tors. These ligands are antagonists (silent, neutral, or
null modulators) at the benzodiazepine binding site.
They exhibit no direct effects at GABA-induced currents
but are able to block the action of positive or negative
allosteric modulators acting at this site.
In addition to the GABA and the benzodiazepine
binding sites there are multiple other binding sites at
GABAA receptors. At least 16 solvent accessible spaces
have been identified in the extracellular and trans-
membrane domain of a GABAA receptor structural
model (Ernst et al., 2005). Five are located at the five
extracellular interfaces between subunits, among those
the benzodiazepine- and the two GABA-binding sites,
five at the transmembrane interfaces, five are located
within the four-helix-bundles forming the transmem-
brane domain of individual subunits, and at least one is
located within the channel pore, mediating the action of
some convulsants (Ernst et al., 2005). Furthermore,
ligand-bound crystal structures of bacterial homologs of
GABAA receptors (GLIC, isolated from Gloeobacter
violaceus; ELIC, isolated from Erwinia chrysanthemi),
the structures of a glutamate-gated channel (isolated
from the nematode Caenorhabditis elegans) for an
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overview, see Sieghart, 2015; and the recently published
crystal structure of the homo-oligomeric b3 GABAA
receptor (Miller and Aricescu, 2014) indicated the
existence of additional ligand-binding sites in the trans-
membrane and extracellular domains (Sieghart, 2015;
Puthenkalam et al., 2016). All these solvent accessible
spaces could function as drug binding pockets. They
differ from each other in their size and their hydrophilic
and hydrophobic properties, depending on the types of
amino acid residues contributing to their formation (Ernst
et al., 2005). In addition, neighboring subunits can influ-
ence the conformation of the pockets via subunit-subunit
interactions, indicating that even pockets formed by
the four-transmembrane helices of two identical a or b
subunits withinGABAA receptors could be different from
each other. And some of the pockets might accommodate
more than one drug at distinct positions (Sieghart, 2015;
Puthenkalam et al., 2016). In addition, binding of a drug
to its pocket(s) can influence the conformation of other
pockets of the receptors, resulting in allosteric interac-
tions with other drugs (Puthenkalam et al., 2016). There
are multiple examples for such allosteric interactions of
drugs in GABAA receptors (Sieghart, 1995).
Possible drug binding sites in the intracellular do-
main of GABAA receptors so far could not be investi-
gated because the structure of the intracellular domain
of these receptors currently is not known. In addition,
drugs could bind to the surface of GABAA receptors and
by that influence their flexibility (Baur et al., 2005,
2013). And binding sites of ions such as Zn2+, Cu2+, or
La3+ in many cases are formed by specific amino acid
residues that differ in distinct receptor subtypes (Sieghart,
2015). In contrast to the GABA and the benzodiazepine
binding sites that are located in the extracellular domain of
GABAA receptors, barbiturates, anesthetics, and neuroac-
tive steroids seem to bind to sites in the transmembrane
domain (Sieghart, 2015; Forman andMiller, 2016; Feng
and Forman, 2018). These compounds not only alloste-
rically modulate GABA-induced currents but at higher
concentrations also can directly activate the ion channel
intrinsic to GABAA receptors in the absence of GABA.
In recent years, more than 100 compounds have been
identified that are able to modulate GABA-induced
currents or to activate directly GABAA receptors via
binding sites different from the benzodiazepine or the
GABA binding site, respectively. For most of these
compounds, their binding sites at GABAA receptors so
far have not been identified.
Drugs that exclusively modulate GABA-induced cur-
rents in an allosteric way are limited in their activity to
those GABAA receptors that are active in a certain task
and therefore have less adverse effects than GABA site
agonists or drugs that are able directly to open the
chloride channel of most if not all GABAA receptors.
Benzodiazepines were the first compounds identified
only to allosterically modulate GABAA receptors, and
due to their anxiolytic, anticonvulsant, sedative, hypnotic,
and muscle relaxant action and their clinical impor-
tance, much of the ensuing effort was directed toward
the development of benzodiazepine site ligands with a
more selective action.
The classic benzodiazepines possess comparable
affinities and efficacies for GABAA receptor subtypes
composed of a1bg2, a2bg2, a3bg2, or a5bg2 subunits
and thus produce comparable behavioral effects. Over
the years, however, a variety of benzodiazepine binding
site ligands from different structural classes have been
developed that are able to differentially interact with
these diazepam-sensitivea1bg2,a2bg2,a3bg2, ora5bg2
receptor subtypes. Their reduced side effect profile in
behavioral experiments in rodents seemed to confirm
the molecular genetic evidence indicating that a1bg2
receptors partially mediate the sedative, anterograde
amnestic, and anticonvulsive actions, and a2bg2 recep-
tors partially mediate the anxiolytic-like action (Löw
et al., 2000). a2bg2 together with a3bg2 receptors seem
to mediate some antinociceptive and muscle relaxant
actions (Crestani et al., 2001;Knabl et al., 2008; Ralvenius
et al., 2015), and a5bg2 receptors mediate the cognitive
effects of benzodiazepine site ligands (Collinson et al.,
2002; Crestani et al., 2002; Rudolph and Möhler, 2014).
Moreover, from such experiments it was concluded that
selective targeting of distinct GABAA receptor subtypes
not only may provide an anxiolytic-like effect without
sedation, but also unveil additional effects, which can be
starting points for the development of an innovative
treatment of pain, cognitive disorders, stroke, schizo-
phrenia, depression, or Down syndrome (Rudolph and
Knoflach, 2011; Rudolph and Möhler, 2014).
C. Aim of the Present Review
Unfortunately, however, many of the compounds
claimed to be GABAA receptor subtype selective have
only been incompletely investigated or, in addition to a
preferential modulation of one receptor subtype, also
significantly modulate other receptor subtypes at sim-
ilar concentrations. Although their differential efficacy
at distinct receptor subtypes reduced side effects and
was beneficial for certain applications, the exact re-
ceptor subtype(s) mediating the behavioral effects of
such compounds cannot be unequivocally delineated.
Uncritical acceptance of a compound as being subtype
selective, therefore, leads to poorly supported conclu-
sions on GABAA receptor subtypes, eliciting compound-
induced behavior, that add confusion to the literature.
In addition, the discrepant in vivo effects of some of
these ligands in rodents and humans recently raised
doubts on the applicability of the concept of receptor
subtype-selectivity as a guide for the development of
clinically useful drugs (Skolnick, 2012).
Here, we provide an up-to-date review on the currently
available GABAA receptor subtype-selective ligands. In
sections II, III, and IV, we discuss methodological
aspects important for the development of such drugs.
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In section V we critically discuss compounds claimed
to be GABAA receptor subtype-selective and provide
information on their actual interaction with various
receptors, on their behavioral actions in vivo, as well as
on their receptor occupancy during their behavioral
actions, if available. Since presenting all the reasonably
characterized compounds with some receptor subtype
selectivity would have been a highly repetitive endeavor,
compounds discussed were selected either because of
their frequent use in behavioral and pharmacological
studies, or because they are the currently most selective
compounds within a compound class for which a reason-
able data set is available. Most of these ligands exert
their actions via the benzodiazepine binding site. Some
of them, however, act via other allosteric binding sites at
GABAA receptors. And a few ligands have been identi-
fied that can be used to selectively activate or inhibit
certain GABAA receptor subtypes by acting via their
GABA binding site. In section VI we discuss the trans-
lational aspect of subtype-selective drugs as exemplified
by the discrepant in vivo effects of some of these ligands in
rodents and man (Skolnick, 2012). In section VIIwemake
proposals for the future development of ligands with
improved anxioselectivity as well as discuss possible ways
to strengthen the conclusions of behavioral studies with
the currently available “receptor subtype-selective drugs.”
II. Receptor Subtype-selective Binding Versus
Subtype-selective Efficacy
Since the discovery of the high affinity “central”
benzodiazepine binding site in the brain (Braestrup and
Squires, 1977; Möhler and Okada, 1977) that later on
turned out to be an allosteric modulatory binding site at
GABAA receptors (Karobath and Sperk, 1979; Sieghart
and Karobath, 1980), more than 100 distinct compound
classes have been identified that could inhibit high
affinity binding of [3H]diazepam, [3H]flunitrazepam,
or [3H]flumazenil to brain membranes. Most of these
compounds have never been investigated for a possible
GABAA receptor subtype selectivity because receptor
subtypes and techniques to investigate them were not
available at the time of their synthesis. Evidence for a
molecular heterogeneity of GABAA receptors was avail-
able soonafter the discovery of the benzodiazepine binding
site (Sieghart and Karobath, 1980). However, recombinant
receptor subtypes could only be expressed and investigated
several years later after the individual subunits had been
cloned and sequenced (Schofield et al., 1987; Levitan et al.,
1988; Pritchett et al., 1989). In those early days, electro-
physiological investigations of recombinant GABAA
receptors were only rarely performed and putative
receptor subtype-selectivity of drugs was deduced from
their differential inhibition of [3H]flunitrazepam or
[3H]flumazenil binding at the recombinant diazepam-
sensitive a1,2,3,5bg2 or diazepam-insensitive a4,6bg2
GABAAreceptor subtypes, respectively (McKayet al., 2004;
Selleri et al., 2003, 2005; Yin et al., 2010), or from two or
three of these receptor subtypes, only (Guerrini et al.,
2007; Lager et al., 2008). However, there are multiple
examples of both, drugs exhibiting a comparable affinity
but a differential efficacy and drugs exhibiting a differ-
ential affinity but a comparable efficacy for modulating
GABA-induced currents of all these receptors (Atack,
2010a,b; Vinkers et al., 2010). It has to be kept in mind
that it is the potency and efficacy of a drug for modulating
GABAA receptor subtypes that is decisively important for
its action and not its affinity for a certain binding site
(Korpi et al., 2002).
This conclusion is strengthened by increasing evi-
dence that most if not all currently available drugs can
interact with several binding sites at the same GABAA
receptor subtype (Sieghart, 2015; Puthenkalam et al.,
2016). Interaction of the drug with some of these binding
sites can be silent, whereas interactionwith other binding
sites can induce or stabilize a conformational change
eliciting some drug effects. Themost impressive examples
for such a pattern are the pyrazoloquinolinones, such
as CGS 9895, which more than three decades ago were
identified as high affinity ligands for the benzodiazepine
site of GABAA receptors (Bennett, 1987). These com-
pounds exhibited anxiolytic and anticonvulsant effects
but produced less sedative and muscle relaxant effects
than benzodiazepines. Only recently it was demonstrated
that CGS 9895 andmost of its structural analogs are high
affinity silent modulators (null modulators, antagonists)
at the benzodiazepine binding site but mediate their low
potency action at various GABAA receptor subtypes via a
novel binding site at the previously not investigateda+b2
interface of GABAA receptors (Ramerstorfer et al., 2011;
Varagic et al., 2013b). Thus it is the functional selectivity
resulting from the interaction of a drugwith all its binding
sites at the respective receptor subtype and at the
concentration used, which is important for the action
of a drug. But of course, a compound highly selective
for the benzodiazepine site of a certain GABAA receptor
subtype might also exhibit a high functional selectivity





A possible functional receptor subtype selectivity can
only be identified by a comparison of drug effects on
GABA-induced currents elicited at various GABAA re-
ceptor subtypes. Unfortunately, however, depending on
the expression system used for generating recombinant
GABAA receptor subtypes (Xenopus laevis oocytes or
cell line type, permanent or transient transfection, ratio
of cDNAs used for transfection, etc.), in addition to
the desired receptor subtype, homo- or heterooligomeric
combinations of subunits can be formed, some of which
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might not occur in vivo (Olsen and Sieghart, 2008;
Boileau et al., 2010; You et al., 2010). Depending on the
exact mixture of recombinant receptors formed in the
expression system the measured pharmacological prop-
erties can be different. And differences in electrophys-
iological protocols between laboratories also can impact
efficacy and potency estimates (de Lucas et al., 2015).
Finally, the GABA concentration used for measuring
allosteric modulation of GABA-induced currents in
recombinantly expressed receptors, strongly influences
the extent of modulation observed. In different studies,
GABA concentrations eliciting 3%–5% (EC3, Baur and
Sigel, 2007; Ramerstorfer et al., 2010), 10% (EC10; Popik
et al., 2006), 20% (EC20; Carling et al., 2006), or even
50% (EC50; Harvey et al., 2002; Yin et al., 2010) of the
maximal currents were used, making comparison of the
data from individual studies even more difficult.
While synaptic GABAA receptors are only partially
saturated by GABA released from single vesicles in the
course of miniature inhibitory postsynaptic currents
(Perrais and Ropert, 1999; Hájos et al., 2000; Rumpel
and Behrends, 2000), they are completely saturated by
GABA released by repetitive action potentials. GABA
concentrations within the synaptic cleft were estimated
to rapidly rise to 1.5–3 mM and decay within a few
hundred microseconds (Mozrzymas et al., 2003). When
receptors are saturated by GABA, allosteric modulators
no longer can enhance the current amplitude but only
prolong the action of GABA. To estimate the action
of a drug under these conditions, one would have to
increase the time of measurement. However, the extent of
GABA-induced current modulation would then strongly
be influenced also by the desensitization of the receptor, a
phenomenon more dominant at higher GABA concentra-
tions and longer measurement times (Jones and West-
brook, 1995). This effect will be even more dramatic with
drugs that allosterically accelerate current decay (Dillon
et al., 1993, 1995; Simeone et al., 2017).
GABAA receptors have a high density at synapses,
but synapses constitute only a small part of the cell
surface. Despite their lower density at the extrasynap-
tic membrane, the overall abundance of extrasynaptic
receptors is higher than that of synaptic receptors
(Nusser and Mody, 2002; Kasugai et al., 2010). Since
GABAA receptors are inserted into the membrane at
extrasynaptic sites (Bogdanov et al., 2006), all GABAA
receptor subtypes, even the synaptic receptors, are also,
at least temporarily, present extrasynaptically. The
GABA concentrations acting at extrasynaptic GABAA
receptors (0.2–2.5 mM; Glykys and Mody, 2007b) acti-
vate extrasynaptic as well as synaptic receptors, al-
though to a different extent (Mortensen et al., 2012;
Karim et al., 2013). For the majority of recombinant
abg2 GABAA receptors, such concentrations are be-
tween GABA EC3 and EC40. Some, but not all ab and
abd receptors, however, are more sensitive to GABA. In
these receptors, 0.2 mM GABA concentrations already
elicit 10%–50% and 2.5 mM GABA concentrations
20%–80% of the maximal GABA-induced currents
(Mortensen et al., 2012; Karim et al., 2013). Nevertheless,
it has been demonstrated that even a1b2g2 receptors,
which exhibit a quite low GABA sensitivity, can be
activated by 0.5 mM GABA, and the resulting GABA
EC1 currents can bemodulated by allosteric modulators
(Li and Akk, 2015).
In addition, measurements at low GABA concentra-
tions (GABA EC3) have technical advantages over mea-
surements at higher GABA concentrations. For instance,
allosteric modulation measured as a percentage of in-
crease in the GABA-induced current in the presence of a
drug ismuch stronger atGABAEC3 than at higherGABA
concentrations, because it is referred to a smaller GABA-
induced current. Differences in the efficacy of a drug for
modulating GABA-induced currents at different receptor
subtypes are thus also more evident at low than at high
GABA concentrations. Measurements are also more re-
producible, becauseGABAEC3 is not in the linear range of
GABA stimulation. Slight differences in the GABA con-
centration from the actual GABA EC3 thus do not matter
as much as similar variations at GABA EC10, EC20, or
EC50. Given all these arguments, it is suggested to
measure allosteric modulation of GABAA receptors at
GABA EC3 whenever technically feasible to increase
the sensitivity of measurements and to allow a better
comparison of pharmacological data.
IV. Importance of Concentration-response
Relationships of “Receptor Subtype-
selective Ligands”
A. Referring Compound Actions to that of Standard
Benzodiazepines Distorts Original Data
In an effort to compare the actions of compounds at
various receptor subtypes with those of chlordiazepoxide
(Blackaby et al., 2006; Carling et al., 2006; Jennings et al.,
2006), diazepam (Griebel et al., 2001; Alhambra et al., 2011;
de Lucas et al., 2015), or zolpidem (Griebel et al., 2001),
their efficacy was often also given relative to the maximal
efficacy of these reference drugs measured in the same
oocyte or cell culture system. Although such presentation
allows for an immediate estimation of whether the
compound exhibits a stronger or weaker effect at a
receptor subtype than the reference compound, it also
distorts the actual efficacy of the compound. For instance,
if a compound exhibits a comparable efficacy at two
receptor subtypes, its relative efficacy at these receptor
subtypes will be different if the efficacy of the reference
compound is different at these receptors. This is the
case, for instance, for diazepam, which exhibits a higher
maximal efficacy for a3b3g2 than for a2b3g2 or for
a1b3g2 and a5b3g2 receptors (Puia et al., 1991;
Ramerstorfer et al., 2010). Furthermore, data presented
relative to diazepam cannot be compared with those
presented relative to chlordiazepoxide or zolpidem in the
842 Sieghart and Savic
absence of information on the efficacy of the reference
compounds used to calculate the results. Thus, unfortu-
nately, important information is lost due to such data
presentation, and the actions of the examined com-
pounds cannot be compared with those of other ligands.
To fully benefit from a comparison with standard benzo-
diazepines, the authors should also provide the original
concentration-response curves of the compounds at the
individual receptor subtypes, as for instance inDias et al.
(2005), Atack et al. (2006b, 2011b), Ren et al. (2010), and
Christian et al. (2015).
B. Maximal Efficacy Hides a Possible Subtype
Selectivity at Lower Concentrations
An apparent lack of receptor subtype selectivity of
most of the published “receptor subtype-selective” com-
pounds, however, can be deduced from three recent
reviews that compared their affinity for the benzodiaz-
epine binding site and their maximal relative efficacy
at various GABAA receptor subtypes (Atack, 2010a,b;
Vinkers et al., 2010). From these overviews it is clear
that even compounds that preferentially modulate a
certain receptor subtype exhibit substantial activity
also at one or more other receptor subtypes when the
maximal efficacy at each receptor subtype is attained.
It has been established previously that, depending on
the behavioral task involved, a 1%–25% in vivo GABAA
receptor occupancy by diazepam (Gardner, 1992; Lippa
et al., 2005) may be sufficient to elicit discernible
anxiolytic or other behavioral effects. A 15%–30% re-
ceptor occupancy (Atack et al., 2010) or an efficacy
greater than 0.1 relative to 1 mM diazepam (Alhambra
et al., 2011) elicits sedation and sleep. Thus even small
effects of drugs at receptor subtypes must not be
ignored. A 10% or 20% increase in living costs signifi-
cantly matters in daily life, and a 10% or 20% enhance-
ment of GABA-induced currents probably also will be
able to elicit some but not all effects that can be elicited
by a stronger enhancement of GABA currents. The
in vivo effects of a drug therefore cannot be exclusively
assigned to that receptor which can bemodulated by the
drug with the highest efficacy.
C. Concentration of Compounds Eliciting
In Vivo Effects
Themaximal efficacy of a drug is usually measured at
a very high drug concentration. In many cases, concen-
trations 1000-fold the Ki value estimated from benzodi-
azepine binding studies were used, resulting in drug
concentrations of 1–10 mM (Street et al., 2004; Carling
et al., 2006; Goodacre et al., 2006). Such concentrations,
at least for benzodiazepine site ligands, only rarely can
be achieved in the brain after pharmacological (rather
than toxicological) doses. It has been demonstrated
that the oral dose of diazepam required to occupy 50%
of all diazepam-sensitive GABAA receptors in rodents
was as low as 1 to 2 mg/kg, resulting in total brain
concentrations of 1 mmol/l and above (Greenblatt and
Sethy, 1990; Müller Herde et al., 2017). But only the
unbound (free) fraction of the total drug concentration
in the brain may bind to receptor sites, and it has been
demonstrated that the free concentrations of drugs
are best correlated with their pharmacological effects
in the brain (Hammarlund-Udenaes, 2010). The un-
bound fraction of benzodiazepine site ligands can
differ substantially and amounts to 3.6% for diaze-
pam or 47.1% for zaleplon (Summerfield et al., 2007).
Under therapeutic conditions, benzodiazepines thus
usually achieve free brain concentrations far below
1 mM.
The free drug concentration at the receptor easily
can be estimated from in vivo receptor occupancy data
of compounds and their concentration-response curves
at individual recombinant receptor subtypes. Assuming
that a 50% receptor occupancy under therapeutic condi-
tions corresponds with the concentration of the com-
pound that generates 50% of its maximal effect at
the most abundant GABAA receptor subtype (a1bg2)
in the brain, the active concentration of the compound at
this receptor and in the brain, as well as the extent of
modulation of the individual receptor subtypes under
these conditions, can be estimated. The data discussed
below indicate that most of the compounds so far
investigated are eliciting their in vivo effects at low
nanomolar concentrations. It is then clear that most if
not all receptor subtypes are fully modulated by the
drug at a close to 100% receptor occupancy. Therefore, it
is reasonable to investigate the receptor subtype selec-
tivity in a concentration range that also can be achieved
in the brain in vivo and that elicits the behavioral
actions of the drug. The best and most reliable way to
measure receptor subtype selectivity, thus, is a compar-
ison of the functional concentration-response curves for
all possible receptor subtypes, because there might be
concentration ranges of a compound in which it exhibits
high receptor subtype selectivity. Only by knowing
these concentrations and the doses required for achiev-
ing these free concentrations in the brain, it is possible
selectively to modulate the respective receptor subtype(s)
in in vitro and in vivo experiments, respectively.
V. Currently Available Compounds Claimed to
Be g-Aminobutyric Acid Type A
Receptor Subtype-Selective
A. Subtype-Selectivity Claimed for Incompletely
Investigated Compounds
Even when the effects of compounds at recombinant
GABAA receptor subtypes were investigated by elec-
trophysiological studies, sometimes not all diazepam-
sensitive receptor subtypes were investigated and in
many cases only the maximal ligand effects, but no
concentration-response curves, were shown at the indi-
vidual receptor subtypes. Receptor subtype selectivity
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was then claimed when a compound exhibited a higher
positive or negative maximal efficacy at the given receptor
as comparedwith other receptors, although other receptors
also were significantlymodulated by the compound (Street
et al., 2004; Goodacre et al., 2006). In addition, a receptor
subtype selectivity was even claimed based on a relatively
selective binding to the benzodiazepine site of a receptor
subtype and a single maximal efficacy at this one receptor
(Achermann et al., 2009; Buettelmann et al., 2009).
B. Compounds Claimed to Selectively Modulate
a1bg2 Receptors
Combined molecular genetic and pharmacological
approaches demonstrated that a1bg2 GABAA receptors
partially mediate the sedative, anticonvulsant, and anter-
ograde amnestic properties of diazepam (Rudolph et al.,
1999;McKernan et al., 2000; Ralvenius et al., 2015). Drugs
selectively modulating a1bg2 GABAA receptors should
thus exhibit sedative and anticonvulsant properties.
1. Zolpidem. The imidazopyridine zolpidem (Fig. 1)
exhibits a 10-fold higher affinity for the benzodiazepine
binding site of a1bg2 than for that of a2bg2 or a3bg2
receptors and an exceptionally low affinity for a5bg2
receptors (Sieghart, 1995). From that itwas concluded that
zolpidem is an a1bg2-selective compound. However, from
the concentration-response curves of zolpidem (Fig. 1) it
can be deduced that there is only a small concentration
range (between 1 and 30 nM) in which zolpidem only
modulates recombinant GABAA receptors composed of
a1bg2 receptors (Ramerstorfer et al., 2010).
At 100 nM concentrations, zolpidem already signifi-
cantly enhanced GABA-induced currents at a2b3g2 or
a3b3g2 receptors from 100% to 132% or 121%, respec-
tively, and at concentrations above 100 nM, which pre-
sumably are achievable in vivo at a moderate to high
zolpidem dose, zolpidem only preferentially, but not
selectively, modulates a1b3g2 receptors. So, by carefully
controlling the concentration of zolpidem, for instance in
electrophysiological experiments using cell cultures or
brain slices, or by local application of zolpidem in in vivo
experiments, it is possible to use this drug for a selective
modulation of a1b3g2 receptors. As expected, due to its
preferential action at a1-containing receptors, zolpidem
exhibits sedative, hypnotic, and anticonvulsive actions
in rodents and humans. The muscle relaxant action of
zolpidem might be mediated by a2- and a3-containing
GABAA receptors (Ralvenius et al., 2015) while any
anxiolytic-like action of zolpidem is behaviorally nonspe-
cific and confounded by sedation (Savic et al., 2004).
Interestingly, zolpidem at clinically relevant con-
centrations was recently demonstrated to enhance
GABA-induced currents in a1b3 receptors composed of
3a1 and 2b3 subunits in a flumazenil-sensitive manner
(Che Has et al., 2016). These receptors contain an a1-a1
interface and thus differ from a1b3 receptors composed
of 2a1 and 3b3 subunits that contain a b3-b3 interface.
Diazepam also was able to modulate the 3a1:2b3-
containing a1b3 receptors, but the efficacy of diaze-
pam was significantly lower for this receptor than that
of zolpidem, and no modulation by either zolpidem or
diazepam was detected at the 2a1:3b3 receptor. To the
best of our knowledge this is the first example of a
stoichiometry-dependent action of a drug. Results in-
dicate that zolpidem is acting via a binding site at the
a1+a12 interface, which obviously mimics the classic
a1+g22 benzodiazepine site. Receptors composed of
a1b3 subunits are expressed in the rat brain (Mortensen
and Smart, 2006; Olsen and Sieghart, 2008). Studies on
recombinant a1b3 receptors have indicated that they
exhibit a stoichiometry of 2a1:3b3 subunits (Tretter
et al., 1997; Baumann et al., 2001). However, other
studies have indicated that recombinant a1b2 (Boileau
et al., 2005) or a6b2 (Im et al., 1995) receptors might be
composed of 3a and 2b subunits. As discussed in Che
Has et al. (2016), zolpidem is not a typical GABAA
receptor hypnotic. Unlike benzodiazepines, zolpidem
modulates tonic GABA currents in the rat dorsal motor
nucleus of the vagus (Gao and Smith, 2010), exhibits
residual effects in mice carrying the point mutation
g2F77I that drastically reduces interaction of zolpidem
with the benzodiazepine binding site of GABAA re-
ceptors (Cope et al., 2005; Ramerstorfer et al., 2010),
and improves speech as well as cognitive and motor
functions in human patients with severe brain injury
(CheHas et al., 2016). The receptors by which zolpidem
mediates these effects are not known. It is thus quite
possible that a1b3 receptors composed of 3a1:2b2
subunits might mediate at least some of these effects.
In any case, these surprising observations on the action
of zolpidem at a1b3 receptors add to previous observa-
tions on the existence of additional benzodiazepine bind-
ing sites atGABAA receptors (Sieghart, 2015). In addition,
they indicate that not all actions of benzodiazepines
or benzodiazepine site ligands can be explained by their
allostericmodulation of the classic benzodiazepine binding
site at thea+g2 interface ofabg2GABAAreceptors. It has
Fig. 1. Chemical structure and concentration-response curves of zolpidem
at various recombinant GABAA receptor subtypes from the rat expressed
in Xenopus laevis oocytes and measured at GABA EC3. The concentra-
tion-response curve of a5b3g2 receptors is overlapping with that of
a6b3g2 receptors. Modified from Ramerstorfer et al., Eur J Pharmacol,
636,18-27, Elsevier, 2010.
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to be kept in mind that these compounds in addition to
their interaction with the benzodiazepine site might
be able to elicit some of their effects via other GABAA
receptor subtypes that do not carry that site, or even
via other effector systems.
2. Indiplon. The pyrazolopyrimidine indiplon (Fig. 2)
has ananomolar affinity for thebenzodiazepinebinding site
of GABAA receptors in various rat brain regions (Sullivan
et al., 2004) andwas claimed to exhibit a 10-fold selectivity
for a1b2g2 over a2-, a3-, or a5-containing receptors in
electrophysiological experiments at recombinant GABAA
receptors from the rat (Petroski et al., 2006). But the
concentration-response curves in Fig. 2 indicate that
this at best is true up to 1 nM concentration. At 10 nM
concentrations, all receptor subtypes investigated be-
come positively modulated by that compound. At high
concentrations, indiplon is a high efficacy positive allo-
steric modulator (full benzodiazepine site agonist) at all
GABAA receptor subtypes investigated. Indiplon exhibits
sedative-hypnotic properties in rodents and humans.
3. Zaleplon, Zopiclone. The structurally related pyr-
azolopyrimidine zaleplon (Fig. 3) exhibits a much lower
Fig. 2. Chemical structure and concentration-response curves of indiplon at various recombinant GABAA receptor subtypes from the rat expressed in
HEK 293 cells. GABA concentration was 3 mM (GABA EC5–10) for all recombinant receptors, and data were measured by patch-clamp recording. The
EC50 values for allosteric modulation of a1b2g2, a2b2g2, a3b3g2, a5b2g2 receptors by indiplon were 2.6, 24, 60, and 77 nM, respectively. Figure
modified from (Petroski et al., 2006).
Fig. 3. Chemical structure and concentration-response curves of zaleplon at various recombinant GABAA receptor subtypes from the rat expressed in
HEK 293 cells. GABA concentration was 3 mM (GABA EC5–10) for all recombinant receptors, and data were measured by patch-clamp recording. The
EC50 values for allosteric modulation of a1b2g2, a2b2g2, a3b3g2, or a5b2g2 receptors by zaleplon were 499, 1098, 1514, or .3000 nM, respectively.
Figure modified from (Petroski et al., 2006).
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affinity for the benzodiazepine binding site of recombi-
nant a1b2g2, a2b1g2, a3b3g2, a2b3g2 receptors from
rat (Ki of 66, 830, 710, 1780 nM, respectively) (Dämgen
and Lüddens, 1999) and, due to its lower potency in
electrophysiological experiments, seems to be a1-selec-
tive up to 100 nM,while at 1mMall receptor subtypes are
modulated by zaleplon (Petroski et al., 2006). At 10 mM
concentration it is a full benzodiazepine site agonist at
a1-3bg2 receptors and a partial agonist at a5bg2 recep-
tors. Similar to zolpidem and indiplon, zaleplon exhibits
sedative-hypnotic properties in rodents and humans.
The structurally dissimilar cyclopyrrolone derivative
zopiclone, the third so-called “Z” drug after zolpidem
and zaleplon, apparently does not exert significant
effects up to 10 nM concentrations at recombinant
a1b2g2, a2b2g2, a3b3g2, a5b2g2 receptors from rat
(Petroski et al., 2006). At 100 nM concentration,
however, it modulates a1b2g2 receptors to about
300% of GABA EC5–10, and a5b2g2 to about 250%.
The allosteric modulation by 100 nM of zopiclone of
recombinanta2b2g2 ora3b3g2 receptors, however, was
below 200% of GABA EC5–10. The EC50 values for the
allosteric modulation of a1b2g2, a2b2g2, a3b3g2,
a5b2g2 receptors by zopiclone, were 158, 598, 1187,
and 146 nM, respectively (Petroski et al., 2006). Zopi-
clone thus is not GABAA receptor subtype-selective at
all. It only preferentially modulates a1b2g2 and
a5b2g2 receptors but also significantly modulates the
other GABAA receptor subtypes at a similar concentra-
tion. Similar to the other “Z” drugs, zopiclone exhibits
sedative-hypnotic properties in rodents and humans.
But this compound also exhibits anxiolytic, anticonvul-
sant, and muscle relaxant properties.
4. b-CCt. The b-carboline-3-carboxylate-t-butyl es-
ter (Fig. 4) was described as a mixed benzodiazepine
agonist-antagonist ligand with .10-fold binding selec-
tivity for a1 over a2, and a3 receptors and .110-fold
selectivity for a1- over a5-containing receptors (June
et al., 2003; Yin et al., 2010). To the best of our knowledge,
no concentration-response curves have been published for
b-CCt, but from the bar graphs in Fig. 4, it can be deduced
that this compound, even at high concentrations, acts
more or less as a null modulator (antagonist) at a1- and
a2-containing receptors, as a weak positive modulator
at a3 and a4 receptors, and a negative modulator at a5
receptors. Thus, despite its at least 10-fold selectivity
for a1 receptors in benzodiazepine binding studies, part
of the effects of b-CCt are presumably exerted via other
GABAA receptor subtypes. Looking at these data, conclu-
sions that the anti-ethanol actions of this compound are
primarily mediated via a1-containing receptors (June
et al., 2003; Yin et al., 2010) seem not to be sufficiently
supported. Nevertheless, in behavioral studies, b-CCt
demonstrated clear differences when directly compared
with flumazenil (Savic et al., 2004), and it is still used as
one of the rare “selective” antagonists at the benzodiaze-
pine binding site (see section V.H).
5. Ro15-1788 (Flumazenil). As can be seen in Fig.
4, the imidazobenzodiazepine flumazenil (Ro15-1788)
(Fig. 5), which originally was assumed to be a general
antagonist at the benzodiazepine site of all GABAA
receptor subtypes, acts as an antagonist only at a1b3g2,
but not at other GABAA receptor subtypes. This conclu-
sion is supported by the concentration-response curves
of Fig. 5, indicating that flumazenil, like other imida-
zobenzodiazepines, is also a positive allosteric modula-
tor at a4b3g2 and a6b3g2 receptors (Ramerstorfer
et al., 2010). The relatively weak positive or negative
allosteric modulation of this compound at these other
receptors as well as changes in GABAA receptor expres-
sion and activity during benzodiazepine treatment or
disease states can at least partially (see also section
V.H) explain a variety of surprising observations when
flumazenil was used in humans as an antagonist of
benzodiazepine actions (Nutt, 1983; Hulse et al., 2015).
C. Compounds Claimed to Selectively Modulate
a2bg2, a3bg2, and a5bg2 Receptors
Since GABAA receptors composed of a1bg2 subunits
seemed to mediate the sedative effects of benzodiazepine
site ligands, the development of drugs with reduced or
Fig. 4. Chemical structure of b-CCt and bar graph showing the maximal
efficacy of this compound as well as that of flumazenil or the b-carboline
ZK93426 in modulating rat recombinant a1b3g2, a2b3g2, a3b3g2, a4b3g2,
and a5b3g2 GABAA receptor subtypes expressed in Xenopus laevis
oocytes. A saturating concentration (1–10 mM) of b-CCt, flumazenil, or
ZK93426 was coapplied over voltage-clamped oocytes along with an
EC50 of GABA. Modified from Yin et al. (2010), Bioorg Med Chem,
18,7548-7564, Elsevier, 2010.
Fig. 5. Chemical structure and concentration-response curves of Ro15-
1788 (flumazenil) at various recombinant GABAA receptor subtypes
from the rat expressed in Xenopus laevis oocytes and measured at GABA
EC3. Modified from Ramerstorfer et al., Eur J Pharmacol, 636,18-27,
Elsevier, 2010.
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eliminated modulation of these receptors became a high
priority of pharmaceutical industry.
1. L-838,417. The triazolopyridazineL-838,417 (Fig. 6)
has a similar low nanomolar affinity for the benzodiaze-
pine binding site of recombinant human GABAA receptors
composed of a1,2,3,5b3g2 subunits and expressed in Ltk
cells. The affinity for a4b3g2 or a6b3g2 receptors was
267 or 2183 nM, respectively. Concentration-response
curves indicate that L-838,417 is a positive allosteric
modulator with nanomolar potency at a2b3g2, a3b3g2,
and a5b3g2 receptors, but is devoid of modulatory actions
at a1b3g2 receptors (Fig. 6). Due to the low affinity at a4-
and a6-containing receptors, physiologic effects of this
compound possiblymediated through these subtypes were
not investigated (McKernan et al., 2000). In contrast to
diazepam, L-838,417 did not impair the motor perfor-
mance of wild-type mice on the rotarod, but it enhanced
locomotor activity. This is a sign of behavioral disinhibition
that might have been caused by a positive allosteric
modulation of a2-containing GABAA receptors under
conditions where it is not opposed by a simultaneous
modulation of a1 receptors (Ralvenius et al., 2015). At
doses that occupied less than 50% of the benzodiazepine
binding sites, L-838,417 retained anticonvulsant activ-
ity in mice and anxiolytic-like activity in rat. The data
indicated that, in rodents, a compoundwith no efficacy at
the a1 subtype does not produce sedation, but retains its
anxiolytic-like properties (McKernan et al., 2000).
2. TPA-023B. The imidazotriazine TPA-023B (Fig. 7)
exhibits a similar low nanomolar affinity for the benzodi-
azepine binding site of human GABAA receptor subtypes
composed of a1,2,3,5b3g2 subunits and expressed in Ltk
cells. The affinity for a4b3g2 or a6b3g2 receptors was
3300 or 4700 nM, respectively. In electrophysiological
experiments, it is a comparably strong modulator of
GABA EC20 at a2b3g2, a3b3g2, and a5b3g2 receptors
and only weakly modulates a1b3g2 receptors (Atack
et al., 2011a). The high receptor occupancy in the rat at
a dose that generates significant anxiolytic-like effects
(87% at 1 mg/kg) indicates that all these receptors are
fullymodulated in vivo at a low dose of the drug already.
Rotarod performance of rats was not significantly
impaired by TPA-023B, even at a dose (10 mg/kg) that
gave essentially complete receptor occupancy. Other
studies indicated that TPA-023B is a nonsedating anxi-
olytic in primates (Atack et al., 2011a). The inset in
Fig. 7 indicates that TPA-023B exhibits less than half of
the maximal efficacy of chlordiazepoxide at a2, a3, and
a5 receptors and about 3% of the maximal efficacy of
chlordiazepoxide at a1 receptors.
3. NS11394, NS16085. The [39-[5-(1-hydroxy-1-methyl-
ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile]
NS11394 (Fig. 8) exhibited a subnanomolar affinity for the
benzodiazepine site of human a1-, a2-, a3-, and a5b3g2
receptors, whereas the affinity for a4b3g2 and a6b3g2
receptors was weak (Ki of 324 and 1009 nM, respec-
tively). Based on oocyte electrophysiology with human
GABAA receptors (GABA EC5–25) relative to 0.5 mM
diazepam, NS11394 was claimed to exhibit a functional
selectivity profile at GABAA receptors of the a5 . a3 .
a2 . a1 order (Mirza et al., 2008). Nevertheless, the
concentration-response curves indicate that, despite
its distinct efficacy for the individual receptor sub-
types, this compound cannot selectively modulate a
single GABAA receptor subtype at any concentration.
NS11394 behaved as an anxiolytic-like compound with
Fig. 6. Chemical structure and concentration-response curves of L838,417
at various human recombinant GABAA receptor subtypes at GABA EC20
expressed in Ltk cells. Figure modified from (McKernan et al., 2000), with
permission by Springer Nature.
Fig. 7. Chemical structure and concentration-response curves of TPA-023B
at various human recombinant GABAA receptor subtypes stably expressed in
Ltk cells and measured at GABA EC20. Inset shows the maximum efficacy at
each receptor subtype relative to that produced by 3 mM of the nonselective
full agonist chlordiazepoxide (CDP). Three micromolars chlordiazepoxide
potentiated GABA EC20 currents by 105%6 6%. Figure modified from Atack
et al. (2011a), with permission by SAGE Publishing.
Fig. 8. Chemical structure and concentration-response curves of NS11394
at various human recombinant GABAA receptor subtypes expressed in
Xenopus laevis oocytes and measured at GABA EC5–25. Data are expressed
relative to the effects of 0.5 mM diazepam on the same oocyte (Christian
et al., 2015) (rel. DZ). Figure modified from Mirza et al. (2008).
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a reduced side-effect profile in rat and mouse, even at full
receptor occupancy (Mirza et al., 2008).
The structurally related compoundNS16085 (de Lucas
et al., 2015), is a2/a3 selective up to a concentration of
3 nM, where it exerts about 10% of the actions of 0.5 mM
diazepam at these receptors. In addition, it is a weak
negative allosteric modulator at a1-containing receptors
and a marginally positive allosteric modulator at a5-
containing receptors. Both NS16085 and NS11394 were
demonstrated to exert an analgesic action by depressing
activity-dependent spinal sensitization after inflamma-
tory injury. These data indicate that potentiation of a2-
and a3-GABAA receptors is sufficient and that positive
modulation at a5-containing GABAA receptors as with
NS11394 is not necessary for inducing this pharmacolog-
ical effect (de Lucas et al., 2015).
D. Compounds Claimed to Selectively Modulate a2bg2
and a3bg2 Receptors
Molecular genetic and pharmacological evidence in-
dicated that a2bg2 receptors predominantly mediate
the anxiolytic effects of diazepam (Löw et al., 2000;
Behlke et al., 2016; Engin et al., 2016). In addition,
a2bg2 and a3bg2 receptors also exhibit antihyperalge-
sic actions (Knabl et al., 2008; Ralvenius et al., 2015)
and at higher concentrations also seem to mediate the
muscle relaxant effects of diazepam. Because a1bg2
receptors seemed tomediate the sedative effects (Rudolph
et al., 1999; McKernan et al., 2000) and a5bg2 receptors
the cognition-impairing effects of classic benzodiazepines
(Collinson et al., 2002; Crestani et al., 2002), avoiding
modulation of both of these receptor types was another
major goal of pharmaceutical industry.
1. Compound 4. The first compound claimed to be
a2 selective was compound 4, a modified quinolone
antibiotic that exhibited anxiolytic-like properties but
did not cause sedation. It produced stronger effects than
L-838,417 at a2-GABAA receptors but did not act via
the benzodiazepine binding site (Johnstone et al., 2004).
Unfortunately, however, only a1b2g2 and a2b2g2 recep-
tors were investigated in this study, and to the best of our
knowledge, no further information on this compound is
available in the literature.
2. Pyridazine Series of a2bg2- and a3bg2-selective
Compounds. In addition to the compoundsmentioned
in the previous section, some anxiolytic-like pyridazine
compounds with no overt signs of ataxia or sedation
have been identified that depending on their exact
structure exhibit a2bg2, a3bg2, and a5bg2 selectivity
(compound 15); a2bg2 and a3bg2 selectivity (com-
pound 14, Fig. 9); or a3bg2 selectivity (compound 16).
These ligands exhibit no modulatory activity at the
a1 subtype, a good central nervous system penetration
and receptor occupancy, and excellent oral bioavail-
ability (Lewis et al., 2006). To the best of our knowl-
edge, no additional studies have been reported on these
compounds.
3. SL-651,498. The pyridoindole derivative SL-651,498
(Fig. 10) exhibited a differential affinity for the benzo-
diazepine site of rat a1-, a2-, a3-, or a5b3g2 receptors
(Ki of 17, 73, 80, or 215 nM, respectively) and based
on electrophysiological measurements was claimed to
be an a2-, a3-selective positive allosteric modulator
(Griebel et al., 2001). But the functional concentration-
response curves at various GABAA receptor subtypes,
relative to zolpidem (a1b2g2) or diazepam (a2b2g2,
a3b2g2, and a5b3g2), provide evidence that this
compound is only a2,a3 selective up to a 10 nM concentra-
tion. In rats, this compound administered at 1–10 mg/kg
elicited anxiolytic-like activity similar to that of di-
azepam and induced muscle weakness, ataxia, or seda-
tion at substantially higher doses ($30 mg/kg) (Griebel
et al., 2001).
4. TPA023. The triazolopyridazine TPA023 (Fig. 11)
has a subnanomolar affinity for the benzodiazepine
binding site of a1-, a2-, a3-, or a5b3g2 receptors and
a reduced affinity for a4b3g2 or a6b3g2 receptors (Ki of
60 or 418 nM, respectively). It was claimed to be selective
for a2b3g2 and a3b3g2 receptors (Atack et al., 2006b).
Fig. 9. Chemical structure and concentration-response curves of com-
pound 14 at various recombinant human GABAA receptor subtypes stably
expressed in L(tk-) cells measured at GABA EC20. Figure modified from
Lewis et al. (2006), with permission of The American Chemical Society.
Fig. 10. Chemical structure and concentration-response curves of
SL-651,498 at various rat recombinant GABAA receptor subtypes stably
expressed in HEK 293 cells measured using whole cell patch-clamp at
GABA EC5–10 and presented relative to zolpidem (a1b2g2) or diazepam
(a2b2g2, a3b2g2, and a5b3g2). DRG indicates the concentration-
response curve of SL-651,498 at dorsal root ganglia neurons in culture
that contain exclusively native a2-containing GABAA receptors. Figure
modified from Griebel et al. (2001).
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However, this compound already produces a subnano-
molar subtle positivemodulation ata5b3g2 receptors. At
1 nM it starts to positively modulate a3b3g2 and at
10 nM concentrations also a2b3g2 receptors. Thus there
is no concentration where this compound exhibits pure
a2/a3 selectivity. This conclusion is supported by other
researchers (Christian et al., 2015; de Lucas et al., 2015),
who identified even stronger interactions of this com-
poundwith other receptor subtypes and indicated that in
their hands TPA023 exhibited only marginal selectivity;
see Fig. 11B (de Lucas et al., 2015) or Fig. 11, C and D
(Christian et al., 2015). In rats, a 50% occupancy of
TPA023 corresponded to an oral dose of 0.42 mg/kg.
TPA023 produced anxiolytic-like effects in rodents at
minimal effective doses of 1–3 mg/kg corresponding to
70%–88% occupancy, while there was no appreciable
sedation up to 30mg/kg (Atack et al., 2006b). The inset in
Fig. 11A indicates that the maximal efficacy elicited by
TPA023 relative to 3 mM chlordiazepoxide is quite weak
at the various GABAA receptor subtypes. This conclusion
is confirmed by Fig. 11B, which presents modulation
of GABA EC10 by TPA023 relative to the modulation
by 0.5 mM diazepam, or by Fig. 11D, which presents
modulation of GABA EC10 by TPA023 relative to 1 mM
diazepam.
5. MRK-409. The structurally related triazolopyrida-
zine MRK-409 (Fig. 12) has a comparable subnanomolar
Fig. 11. Chemical structure and concentration-response curves of TPA023. (A) Figure modified from Atack et al. (2006b), generated at various
recombinant human GABAA receptor subtypes (containing b3 subunits) stably expressed in L(tk-) cells measured at GABA EC20. Inset shows the
maximum efficacy of TPA023 at each subtype relative to that produced by 3 mM of the nonselective full agonist chlordiazepoxide (CDP). (B) Figure
modified from de Lucas et al. (2015), Biochemical Pharmacology, 93, 370-379, Elsevier, 2015, generated at various recombinant human GABAA
receptor subtypes (containing b2 subunits) expressed in Xenopus laevis oocytes measured at GABA EC10 relative to 0.5 mM diazepam in the same
oocyte. Inset shows % of modulation of GABA EC10 by 0.5 mM diazepam at the individual receptors. The percentages given at the right of the curves
represent the Emax elicited by TPA023 as % of the effect of 0.5 mM diazepam (de Lucas et al., 2015). (C and D) Figures modified from Christian et al.
(2015) with permission by the American Physiological Society, generated with TPA023 at various recombinant human GABAA receptor subtypes
(containing b3 subunits) expressed in Xenopus laevis oocytes and measured at GABA EC10. (C) Data represent % modulation of GABA EC10 by
TPA023. (D) Data represent % modulation of GABA EC10 by TPA023, and normalized to the current potentiation produced by 1 mM diazepam that
elicited a near maximal response.
Fig. 12. Chemical structure and concentration-response curves of
MRK-409 at various recombinant human GABAA receptor subtypes
stably expressed in mouse L(tk-) cells, measured using whole cell patch-
clamp electrophysiology at GABA EC20. Inset shows maximal potenti-
ation at each cell type expressed relative to that produced by 3 mM of
the nonselective full benzodiazepine site agonist chlordiazepoxide.
Figure modified from Atack et al. (2011b) with permission by SAGE
Publishing.
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affinity for the benzodiazepine binding site of recombi-
nant human a1b3g2, a2b3g2, a3b3g2, a5b3g2 GABAA
receptor subtypes and a lower affinity for a4b3g2 or
a6b3g2 receptors (Ki = 78 or 980 nM, respectively). In
electrophysiological studies it is relatively selective for
a3 receptors comparedwitha1b3g2,a2b3g2, anda5b3g2
receptors at subnanomolar but not at higher concentra-
tions (Fig. 12). MRK-409 produced anxiolytic-like activ-
ity in rodents and primates, with minimum effective
doses corresponding to occupancies from 35% to 65%,
depending on the particular model used, and first overt
signs of sedation at occupancies greater than 90% (Atack
et al., 2011b). The inset in Fig. 12 indicates thatMRK-409,
relative to 3mMchlordiazepoxide, behaves as aweak to
moderate partial agonist at the benzodiazepine binding
site of diazepam-sensitive GABAA receptor subtypes.
6. SH-053-29-N (HZ166), MP-III-024, KRM-II-81.
The imidazobenzodiazepine SH-053-29-N (Fig. 13) ex-
hibits a moderate affinity for the benzodiazepine site of
GABAA receptor subtypes (Ki of 300, 160, 527, or 82 nM
for a1b3g2, a2b3g2, a3b3g2, or a5b3g2 receptors,
respectively) (Fischer et al., 2010) and was claimed to
be an a2/a3 GABAA receptor-selective benzodiazepine.
MP-III-024, the methyl ester analog of the ethyl ester
HZ166, exhibited a slightly lower efficacy than HZ166,
but a similar preferential activity at a2b3g2 and
a3b3g2 receptors (Fischer et al., 2017). KRM-II-81, a
derivative of HZ166 carrying an oxazole ring instead of
the ethyl ester of HZ166, exhibited a higher potency and
efficacy for a2b3g2 and a3b3g2 receptors (Lewter et al.,
2017). However, the respective concentration-response
curves indicate that all three of these compounds already
at 100 nM concentrations significantly modulate a1 and
a5 receptors in addition to a2/a3 receptors (Rivas et al.,
2009; Fischer et al., 2010, 2017; Lewter et al., 2017)
(Fig. 13). MP-III-024 and KRM-II-81 exhibited signifi-
cant antinociceptive effects (Fischer et al., 2017; Lewter
et al., 2017). HZ166 produced some anticonvulsive
(Rivas et al., 2009), anxiolytic-like (Savic et al., 2010),
and antihyperalgesic effects (Di Lio et al., 2011), while
it was devoid of sedation and motor impairment in
rodents in some (Rivas et al., 2009; Di Lio et al., 2011),
Fig. 13. Chemical structure and concentration-response curves of
SH-053-29-N (HZ166) at various rat recombinant GABAA receptor
subtypes expressed in Xenopus laevis oocytes and measured at GABA
EC3. Figure modified from Rivas et al. (2009) with permission of The
American Chemical Society.
Fig. 14. Chemical structure of baicalin and concentration-response curves of diazepam (DZ, open circles) and baicalin (filled triangles) on various
human recombinant GABAA receptor subtypes expressed in HEK 293T cells under whole cell patch-clamp at GABA EC20. Modified from Wang et al.,
Neuropharmacology, 55:1231–1237, Elsevier, 2008.
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but not all, studies (Savic et al., 2010). In the latter
study, the magnitude of the hypolocomotor effect of
30 mg/kg SH-053-29-N in rats was somewhere in the
middle between the effects of two tested doses of diazepam
(1.25 and 2.5 mg/kg) (Savic et al., 2010).
7. Baicalin. A variety of flavonoids have been demon-
strated to interact with the benzodiazepine site of GABAA
receptors and some of them also have some preferences for
certain GABAA receptor subtypes (Furtmueller et al., 2008;
Wang et al., 2008; Karim et al., 2012a). The flavonoid
baicalin (Fig. 14) has been isolated from the traditional
Chinese herb Huangqin, the dry root of Scutellaria
baicalensis Georgi, and interacts with the benzodiaz-
epine binding site of GABAA receptors with a poor Ki
value of 77.1 mM. It produced anxiolytic-like effects in
a Vogel conflict test and elevated plus maze test, and
was devoid of sedation, myorelaxation, anticonvulsant,
amnesic, and motor incoordination effects. In whole
cell patch-clamp studies at 1 mM concentrations, baicalin
showed significant preference for a2- and a3-containing
compared with a1- and a5-containing GABAA receptor
subtypes (Wang et al., 2008).However, baicalin in addition
also is a known prolyl endopeptidase inhibitor (Tarragó
et al., 2008) and induces apoptosis in pancreatic cancer
cells (Takahashi et al., 2011).
8. 6-Hydroxyflavone. The flavonoid 6-hydroxyflavone
(Fig. 15) has a quitemoderate affinity of 1.3–4.9mMfor the
benzodiazepine binding site of human diazepam-
sensitive GABAA receptor subtypes expressed in HEK
293T cells (Ren et al., 2010) and preferentially modu-
lates a2- and a3-containing GABAA receptors in elec-
trophysiological experiments. This compound produced
anxiolytic-like effects in mice without the side effects
observed with classic benzodiazepines (Ren et al., 2010).
It should be kept in mind, however, that flavonoids
can mediate their effects via multiple binding sites at
GABAA receptors (Hanrahan et al., 2015) and that the
actions of flavonoids are not necessarily limited to GABAA
receptors. Depending on their structure they also can
interact with nicotinic acetylcholine receptors, serotonin
type 3A receptors, glutamate AMPA/kainate receptors and
others (Johnston and Beart, 2004).
9. Fa131. The flavan-3-ol derivative Fa131 (Fig. 16)
does not inhibit [3H]flunitrazepam binding to rat cortical
membranes. However, at low micromolar concentrations
it is a positive allosteric modulator of human recombi-
nant a1,2,3,5b2g2L and a1b2 receptors expressed in
Xenopus laevis oocytes, and this enhancement is not
mediated via the benzodiazepine site, as it could not be
blocked by the benzodiazepine site antagonist flumaze-
nil (Fernandez et al., 2008). Fa131 preferentially mod-
ulates a2 receptors below 3 mM concentrations and
induces anxiolytic-like but no sedative effects in ro-
dents. This compound highlights the potential of target-
ing nonbenzodiazepine allosteric sites in the search for
new anxioselective drugs.
10. AZD7325. The cinnoline-carboxamide AZD7325
(Fig. 17) was claimed to be an a2/a3 GABAA receptor-
Fig. 15. Chemical structure of 6-hydroxyflavone and concentration-effect curves of diazepam (DZ, open circles) and 6-hydroxyflavone (filled circles) on
human recombinant GABAA receptor subtypes expressed in HEK 293T cells under whole cell patch-clamp at GABA EC20. Modified from Ren et al.,
Biochemical Pharmacology 79: 1337–1344, Elsevier, 2010.
Fig. 16. Chemical structure and concentration-response curves of Fa131
at various human recombinant GABAA receptor subtypes expressed in
Xenopus laevis oocytes and measured at GABA EC5. Modified from
Fernandez et al., Neuropharmacology, 55: 900–907, Elsevier, 2008.
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selective partial modulator acting via the benzodiazepine
site (Christian et al., 2015; Jucaite et al., 2017).
Concentration-response curves at GABA EC10 and
human axb3g2 receptors expressed in Xenopus laevis
oocytes indicate, however, that a5 receptors also are
modulated to a small extent already at nanomolar
concentrations (Christian et al., 2015). Positron emis-
sion tomography studies demonstrated that up to 80%
receptor occupancy could be reached in the human
brain by AZD7325 for its anxiolytic effects without
overt sedation or cognitive impairment. The declared
lack of side effects in humans can be explained by an
insufficient modulation of a1- and a5-containing re-
ceptors under these conditions (Jucaite et al., 2017).
E. Compounds Claimed to Selectively Modulate
a3bg2 Receptors
So far, no reasonably investigated compound has been
identified that modulates only a2bg2 GABAA receptors
with a certain selectivity, but several compounds have
been identified that were claimed to selectively modulate
a3b3g2 receptors.
1. TP003. The imidazopyridin-3-yl-biphenyl-2-
carbonitrile TP003 (Fig. 18) has a comparable subna-
nomolar affinity for the benzodiazepine binding site of
recombinant human a1-, a2-, a3-, and a5b3g2 GABAA
receptors (Ki between 0.3 and 0.5 nM), and a low affinity
for a4- or a6b3g2 receptors (Ki of 2.4 or 1.8 mM,
respectively) and was declared to be an a3b3g2-selective
positive allosteric modulator (Dias et al., 2005). The
complete functional concentration-response curves (at
GABA EC20, referred to the potentiation of 3 mM
chlordiazepoxide) indicate, however, that due to the
exceptionally high potency of this compound this at best
holds true only at concentrations up to 1 nM (Fig. 18A);
even before 10 nM, TP003 additionally modulates
a2b3g2 and a5b3g2 receptors. More recently, stronger
effects of TP003 at various receptor subtypes were
demonstrated (de Lucas et al., 2015) (Fig. 18B) when
GABA EC10 was used and it was concluded that TP003
exhibits only marginal receptor subtype selectivity.
In Table 1 of Christian et al. (2015), data are presented
indicating that TP003 exhibits no selectivity at all for
a3-containing GABAA receptor subtypes.
Nevertheless, based on the apparent selectivity of
TP003 for a3-containing receptors and on experiments
Fig. 17. Chemical structure and concentration-response curves of AZD7325 at various human recombinant GABAA receptor subtypes expressed in
Xenopus laevis oocytes and measured at GABA EC10. (A) % Modulation of GABA EC10. (B) The same data relative to the current potentiation produced
by 1 mM diazepam, which elicited near maximal response at all receptor subtypes investigated. Figure modified from Christian et al. (2015) with
permission by the The American Physiological Society.
Fig. 18. Chemical structure and concentration-response curves of TP003.
(A) Figure modified from Dias et al. (2005) with permission of the Society
of Neuroscience, generated at various human axb3g2 recombinant
GABAA receptor subtypes stably expressed in L(tk-) cells and measured
at GABA EC20. Data presented are referred to the potentiation of 3 mM
chlordiazepoxide. The inset histogram shows % modulation of GABA
EC20 by 3 mM chlordiazepoxide (CDP) at these receptor subtypes. (B)
Figure modified from de Lucas et al., Biochemical Pharmacology 93, 370–
379, Elsevier, 2015, generated at various human recombinant GABAA
receptor subtypes (containing b2 subunits in this case) expressed in
Xenopus laevis oocytes and measured at GABA EC10 relative to 0.5 mM
diazepam in the same oocyte. Inset shows % of modulation of GABA EC10
by 0.5 mM diazepam at the individual receptors. The percentages given at
the right of the curves represent the Emax elicited by TP003 as % of the
effect of 0.5 mM diazepam.
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indicating that TP003 generated anxiolytic-like effects
even in mice with a point mutation that renders
a2-containing receptors benzodiazepine insensitive (Dias
et al., 2005), it was claimed that a3-containing receptors
have a significant role in mediating the anxiolytic effects
of benzodiazepines. However, in contrast to diazepam,
which not only is inactive at the abg2 GABAA receptor
subtypes carrying the point mutation a2H101R but also
at receptors carrying the mutations a1H101R, a3H126R, or
a5H105R that are also used for demonstrating the function
of the respective receptor subtypes in the brain (Rudolph
and Knoflach, 2011; Rudolph and Möhler, 2014), other
ligands of the benzodiazepine site, such as bretazenil
or Ro15-4513, are even more active at all these point-
mutated receptors (Benson et al., 1998). The anxiolytic
effects of TP003 in a2-point-mutated mice thus cannot be
interpreted in the absence of evidence that TP003 is really
inactive at recombinant a2H101Rbg2 receptors. Moreover,
due to the only marginal selectivity of TP003, the in-
volvement of other receptor subtypes such as a5-contain-
ing receptors in anxiolytic-like activity (Behlke et al.,
2016), aswell as the absence ofmolecular genetic evidence
indicating an involvement of a3b2g2 receptors in the
anxiolytic-like action (Löw et al., 2000), it has to be
concluded that an anxiolytic-like role of a3-containing
GABAA receptors is not supported by the available data.
2. YT-III-31. The imidazobenzodiazepine YT-III-31
(Fig. 19) preferentially modulates the recombinant
a3b3g2 GABAA receptor subtype (Namjoshi et al., 2013).
Although the concentration-response curves at first sight
seem to point to a high selectivity for a3 receptors, this
compound also significantly modulates most investi-
gated receptor subtypes at 10 nM concentrations. In
rats, YT-III-31 produced anxiolytic-like actions in a
narrow dose range (,10 mg/kg) but sedation at higher
doses (Batinic et al., 2018). The concentration-response
curves of Fig. 19 predict moderate potentiation of a3 as
well as a2 and a5 receptors before sedative effects
mediated via a1 receptors are activated.
3. a3IA. The pyridone a3IA (Fig. 20) has a modest
affinity for the benzodiazepine binding sites of a1-, a2-,
a3-, or a5b3g2 receptors (Ki = 1029, 323, 82, or 410 nM,
respectively, and a very weak affinity for that of a4- or
a6b3g2 receptors (Ki . 10,000 nM) and was claimed
to be an a3b3g2 receptor-selective negative allosteric
modulator (Atack et al., 2005). Concentration-response
curves measured at GABA EC20, however, indicate that
this only holds true up to a concentration of 30 nM, as at
100 nM concentrations, receptors composed of a1b3g2
and a2b3g2 subunits also become negatively modulated
by this drug. At doses that produce relatively low levels of
occupancy (12%) in the rat cerebellum, a brain region that
contains predominantly a1- and a6-containing GABAA
receptors and only 2% of a3- and 7% of a2-containing
receptors (Pöltl et al., 2003), this compound elicited an
anxiogenic-like effect similar to FG7142, and this effect
could be blocked by the benzodiazepine site antagonist
flumazenil (Atack et al., 2005). From the concentration-
response curves in Fig. 20 it can be concluded that the
concentration eliciting a 12% occupancy of a1 receptors
amounts to .100 nM a3IA. At that concentration,
a3IA elicits a similar negative allosteric modulation at
a3b3g2 receptors as the anxiogenic compound FG7142.
F. Compounds Claimed to Selectively Modulate
a5bg2 Receptors
A combination of molecular genetic and pharmacolog-
ical approaches indicated that a5bg2 receptors mediate
the unwanted cognitive effects of diazepam and that a
negative modulation of these receptors enhances learn-
ing and memory (Collinson et al., 2002; Crestani et al.,
2002). Other experiments indicated that reducing exces-
sive tonic inhibition by negative allosteric modulators at
a5bg2 receptors may promote functional recovery from
stroke (Clarkson et al., 2010). Therefore, the main effort
of researchers was directed to the development of
negative allosteric modulators of a5bg2 receptors.
However, recent evidence indicated beneficial effects
of positive allostericmodulators at a5-containingGABAA
receptors on cognition in the aging brain (Koh et al., 2013),
in schizophrenia (Gill and Grace, 2014), or in neuropsy-
chiatric disorders characterized by cognitive deficits due
Fig. 19. Chemical structure and concentration-response curves of YT-III-
31 at various rat recombinant GABAA receptor subtypes expressed in
Xenopus laevis oocytes and measured at GABA EC3. Modified from
Namjoshi et al., Bioorg Med Chem, 21, 93–101, Elsevier, 2013.
Fig. 20. Chemical structure and concentration-response curves of a3IA
at various human recombinant axb3g2 GABAA receptor subtypes stably
expressed in L(tk-) mouse fibroblast cells and measured at GABA EC20.
The shaded areas represent the range of inverse agonist efficacies across
subtypes for the nonselective partial inverse agonists FG7142 or the
nonselective full inverse agonist DMCM. Figure modified from Atack
et al. (2005). Reprinted with permission of John Wiley & Sons, Inc.
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to impaired memory interference management (Engin
et al., 2015). These observations point to a more complex
bidirectional modulation of cognition by a5-containing
GABAA receptors andprovidenew impetusalso to develop
selective positive allosteric modulators at a5bg2 recep-
tors. This impetus is further enhanced by recent findings
that positive allosteric modulators at a5-containing
GABAA receptors have beneficial effects in the treat-
ment of asthma (Gallos et al., 2015) ormedulloblastomas
(Jonas et al., 2016).
1. SH-053-R-CH3-29F, MP-III-022. One of the first
relatively a5b3g2-selective positive allosteric modula-
tors reported with concentration-response curves was
the imidazobenzodiazepine SH-053-R-CH3-29F (Savic
et al., 2010) (Fig. 21). This compound has a moderate
affinity for the benzodiazepine binding site of a5 receptors
(Ki = 95.2 nM) and a low affinity for a1-, a2-, or a3b3g2
receptors (Ki = 759, 948, or 768 nM, respectively) (Fischer
et al., 2010). In electrophysiological experiments, SH-053-
R-CH3-29F is selective for a5 receptors up to a 30 nM
concentration. At 100 nM concentration, this compound
significantly enhances GABA EC3 currents at a1b3g2,
a2b3g2, a3b3g2, and a5b3g2 receptors from 100% to
111%, 124%, 125%, and 183%, respectively (Fischer
et al., 2010; Savic et al., 2010). At doses up to 30 mg/kg,
SH-053-R-CH3-29F depressed locomotion but did not
induce cognitive impairment or anxiolytic-like activity
(Savic et al., 2010). In addition, it was demonstrated to
relax precontracted intact airway smooth muscle cells
(Gallos et al., 2015).
Ester to amide substitution in SH-053-R-CH3-29F led
to MP-III-022, with improved selectivity, efficacy, and
kinetic behavior as a positive modulator of GABAA
receptors containing the a5 subunit (Stamenic et al.,
2016). While at doses 1–10 mg/kg it was devoid of ataxia,
sedation, or an influence on the extent of anxiety-related
behavior in rats, at the dose of 10 mg/kg MP-III-022
caused a strong positive modulation of a5b3g2 receptors
and mild, but significant, muscle relaxation (Stamenic
et al., 2016).
2. a5IA. The triazolopyridazine a5IA (Fig. 22) was
demonstrated to bind with equivalent subnanomolar
affinity (0.5–0.9 nM) to the benzodiazepine binding
site of recombinant humanGABAA receptors containing
a1-, a2-, a3-, or a5b3g2 subunits and possessed much
lower affinity (Ki = 60 or 418 nM, respectively) for
receptors containing a4 or a6b3g2 subunits. a5IA was
declared to be an a5 receptor-selective negative alloste-
ric modulator (Dawson et al., 2006), but the data
presented for human recombinant ab3g2 GABAA re-
ceptors indicate that there was no concentration where
this compound acted exclusively via a5 receptors (Fig.
22). Interestingly, however, data obtained from differ-
ent expression systems [Xenopus oocytes or L(tk-) cells
stably expressing the same human receptors), depend-
ing on the receptor subtype investigated were found to
be significantly different (Dawson et al., 2006). A possible
additional action of this compound via a4b3g2 receptors
was not investigated. Other studies indicated that with
oral doses of 0.1, 1.0, and 10 mg/kg, GABAA receptor
occupancies in Sprague-Dawley rat brain were 27%, 79%,
and 87%, respectively, 2 hours after oral administration
(Atack et al., 2009a). This compound significantly en-
hanced performance in a rat hippocampal-dependent test of
learning and memory with a minimum effective oral
dose of 0.3 mg/kg. It was not convulsant or anxiogenic in
rodents and did not impair performance in the mouse
rotarod test (Dawson et al., 2006).
3. a5IA-II. The structurally related triazolopyrida-
zine a5IA-II (Fig. 23) exhibited a comparably high affinity
for the benzodiazepine site of a1-, a2-, a3-, or a5b3g2
receptors (Ki = 1.4, 2.7, 1.4, or 0.8 nM, respectively). The
affinity for a4- or a6b3g2 receptors was not investigated.
a5IA-II was claimed to be a selective negative allosteric
modulator at a5bg2 receptors (Collinson et al., 2006).
Nevertheless, there is no concentration where this com-
pound modulates only a5bg2 receptors. Occupancy stud-
ies indicated that a dose of 1 mg/kg a5IA-II produced
sustained and high level occupancy in rats, with maxi-
mum occupancy (80%) being achieved within 15 minutes
of dosing. Assuming that receptor occupation parallels
receptor modulation, this indicates that an in vivo
Fig. 21. Chemical structure and concentration-response curves of
SH-053-R-CH3-29F at various rat recombinant GABAA receptor subtypes
expressed in Xenopus laevis oocytes and measured at GABA EC3.
Modified from Savic et al., Prog Neuropsychopharmacol Biol Psychiatry,
34:376–386, Elsevier, 2010.
Fig. 22. Chemical structure and concentration-response curves of a5IA
at various human recombinant axb3g2 GABAA receptor subtypes stably
expressed in L(tk-) mouse fibroblast cells and measured at GABA EC20.
Figure modified from Dawson et al. (2006).
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application of this drug at 1 mg/kg probably is able to
modulate not only a5b3g2 receptors. Behavioral stud-
ies indicated that a5IA-II induced an enhancement of
cognitive performance in the Morris water maze, affect-
ing encoding and recall but not the consolidation phases of
performance (Collinson et al., 2006).
4. MRK-016. The pyrazolotriazine MRK-016 (Fig. 24)
exhibited a high and essentially equivalent affinity for
the benzodiazepine binding site of human recombinant
GABAA receptors composed of a1-, a2-, a3-, or a5b3g2
subunits (Ki value range, 0.83–1.4 nM). The affinity was
much lower for a4- or a6b3g2 receptors (Ki = 400 or
4100 nM, respectively). MRK-016 was declared to be a
selective negative modulator at a5 receptors (Atack
et al., 2009b). However, there is no concentration where
this compound only modulates a5b3g2 receptors (Fig.
24). Other experiments indicated that the maximal
occupancies of GABAA receptors in the rat brain after
1, 3, or 10 mg/kg orally, measured 0.5 hour after dosing,
were 79%, 81%, and 91%, respectively, again suggesting
that a5b3g2 receptors were not exclusively modulated
in vivo under these conditions (Atack et al., 2009b).
MRK-016 increased long-term potentiation in mouse
hippocampal slices to a greater extent than a5IA, consis-
tent with its greater a5-inverse agonism, and enhanced
cognitive performance in the Morris water maze. In mice,
it was not anxiogenic, not proconvulsant, and did not
produce kindling. Nevertheless, it was poorly tolerated in
elderly subjects, and this precluded its further develop-
ment (Atack et al., 2009b). Given the recent evidence that
negative allosteric modulators at a5-containing GABAA
receptors improve cognitive function in young, but not in
aged, rats (Koh et al., 2013), it is not surprising that this
extremely strong negative allosteric modulator at a5
receptors was poorly tolerated in elderly subjects.
5. L-655,708. The imidazobenzodiazepine L-655,708
(Fig. 25) exhibited a 30–70-fold selectivity fora5- compared
with a1-, a2-, and a3b3g2 receptors (Ki of 1, 70, 48, and
31 nM, respectively) in benzodiazepine binding studies
and was described as a highly selective weak negative
allosteric modulator at a5b3g2 receptors as indicated
by its concentration-response curves (Atack et al.,
2006a). However, due to the exceptionally high potency
of this compound at a5b3g2 receptors, this is true up to
only a10nMconcentration (Fig. 25A). L-655,708 enhanced
long-term potentiation in a mouse hippocampal slice
model. Under conditions where it achieved 75% occupancy
of a5 and 22% occupancy of a1, a2, and a3 receptors,
L-655,708 enhanced cognition in the Morris water maze,
but was devoid of proconvulsant activity.
The data presented, however, are different from our
own data presented in Fig. 25B (Ramerstorfer et al., 2010).
Fig. 23. Chemical structure and concentration-response curves of
a5IA-II at various human recombinant GABAA receptor subtypes stably
expressed in L(tk-) mouse fibroblast cells and measured at GABA EC20.
Adapted with permission, Springer, Psychopharmacology (Berl), Collinson
et al. (2006).
Fig. 24. Chemical structure and concentration-response curves of MRK-
016 at various human recombinant GABAA receptor subtypes stably
expressed in L(tk-) mouse fibroblast cells and measured at GABA EC20.
Figure modified from Atack et al. (2009b).
Fig. 25. Chemical structure and concentration-response curves of
L-655,708. (A) Modified from Atack et al., Neuropharmacology, 51:
1023–1029, Elsevier, 2006a. Data were generated at various human
recombinant GABAA receptor subtypes stably expressed in L(tk-) mouse
fibroblast cells and measured at GABA EC20. The shaded areas
represent the range of inverse agonist efficacies across subtypes for the
nonselective partial inverse agonists FG7142 or the nonselective full
inverse agonist DMCM. (B) Figure modified from Ramerstorfer et al., Eur
J Pharmacol, 636,18–27, Elsevier, 2010. Data were generated at various
rat recombinant GABAA receptor subtypes expressed in Xenopus laevis
oocytes and measured at GABA EC3. The concentration-response curve of
a2b3g2 receptors is overlapping with that of a1b3g2 receptors.
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The opposite direction of a3b3g2 receptor-modulation
by this compound in the two data sets is especially
puzzling. Presumably, the concentration of applied
GABA (EC20 vs. EC3) or the exact experimental condi-
tions affected the final results. It can be assumed that at
lowGABA concentrations, predominantly one of the two
GABA binding sites of GABAA receptors is occupied. At
higher GABA concentrations, increasingly both sites at
the receptors become occupied by GABA. Interaction of
a compound with a receptor containing two occupied
GABA sites might cause a conformational change
different from that with only one site occupied, opening
the possibility that extent and direction of the allosteric
modulation by some compounds, depending on the
receptor subtype investigated, could also depend on
the GABA concentration used. However, so far, this
possibility has not been systematically investigated for
any compound. In any case, this compound, similar to
other imidazobenzodiazepines, additionally exhibits
significant positive modulatory effects at a4b3g2 and
a6b3g2 receptors (Fig. 25B) that were not investigated
in previous studies and could have contributed to the
behavioral effects observed.
6. PWZ-029. The imidazobenzodiazepine PWZ-029
(Fig. 26) exhibited a moderate affinity for the benzodi-
azepine binding site of a5b3g2 receptors (Ki of 38.8 nM)
andKi values of.300 nM for all other GABAA receptors
investigated. In electrophysiological studies it was
demonstrated to be a relatively selective negative
allosteric modulator at a5b3g2 receptors up to a
concentration of 100 nM (Harris et al., 2008; Savic
et al., 2008a), while this compound modulates other
receptor subtypes by less than 10%. At concentra-
tions .100 nM this compound exhibits weak positive
modulatory effects at a1b3g2, a2b3g2, a3b3g2, a4b3g2
or a6b3g2 receptors (Harris et al., 2008). This com-
pound was able to attenuate scopolamine-induced
contextual memory impairment in mice (Harris et al.,
2008) and improved passive avoidance learning in rats
(Savic et al., 2008a), indicating that it facilitates some
aspects of cognitive performance.
7. RY-024. The imidazobenzodiazepine RY-024
(Fig. 27) exhibits nanomolar affinities for the benzodi-
azepine site of a1-, a2-, a3-, a5-, a6b3g2 receptors
(Ki values of 26.9, 26.3, 18.7, 0.4, 5.1 nM, respectively)
and a unique spectrum of actions at these receptor
subtypes (Harris et al., 2008). It is a negative allosteric
modulator at a5b3g2, a1b3g2, and a2b3g2; has no
action via a3b3g2; and is a positive allosteric modulator
at a4b3g2 and a6b3g2 receptors. Due to its high
potency for a5 receptors, this compound only up to a
10 nM concentration can be considered a more or less
selective a5b3g2-negative modulator. Nevertheless,
based on receptor binding studies only, which indicated
an about 70-fold selectivity of this compound for a5 over
a1 receptors, in experiments with RY024 it was claimed
that a5-containing receptors play an important role in
regulating the reinforcing, motor-impairing, and sedative
effects of alcohol in outbred rats (McKay et al., 2004).
8. RO4938581. The imidazobenzodiazepine RO4938581
(Fig. 28) has a high affinity (Ki of 4.6 nM) for the
benzodiazepine site of rat a5b3g2 receptors and a much
lower affinity for that of a1b3g2, a2b3g2, or a3b3g2
receptors (Ki values of 174, 185, or 80 nM, respectively)
and was also suggested to be an a5-selective negative
allosteric modulator (Ballard et al., 2009). The incom-
plete presentation of the concentration-response curves at
Fig. 26. Chemical structure and concentration-response curves of PWZ-
029 at various rat recombinant GABAA receptors expressed in Xenopus
laevis oocytes and measured at GABA EC3. The concentration-response
curves at a4b3g2 and a6b3g2 receptors were measured at GABA EC20.
Figure modified from Harris et al. (2008) with permission of The
American Chemical Society.
Fig. 27. Chemical structure and concentration-response curves of RY024
at various rat recombinant GABAA receptors expressed in Xenopus laevis
oocytes and measured at GABA EC20. Figure modified from Harris et al.
(2008) with permission of The American Chemical Society.
Fig. 28. Chemical structure and concentration-response curves of
RO4938581 at various rat recombinant GABAA receptor subtypes stably
expressed in HEK 293 cells and measured using the whole cell patch-
clamp technique at GABA EC20. Adapted with permission, Springer,
Psychopharmacology (Berl), Ballard et al. (2009).
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the remaining receptor subtypes as well as the missing
data for a4b3g2 and a6b3g2 receptors cast doubt on
that claim. The degree of a5 receptor occupancy in the
rat hippocampus produced by RO4938581 at oral doses
of 0.1, 1.0, and 10 mg/kg was 30%, 74%, and 90%,
respectively (Ballard et al., 2009). In experiments with
mice, rats, and monkeys, this compound enhanced
hippocampal long-term potentiation and was cognition
enhancing at 30% receptor occupancy in the rat, while
being devoid of anxiety-like and proconvulsant actions
(Ballard et al., 2009).
9. TB21007. The 6,6-dimethyl-3-(2-hydroxyethyl)-
thio-1-(thiazol-2-yl)-6,7-dihydro-2-benzothiophen-4(5H)-one
(TB21007) (Fig. 29, compound 43 in Chambers et al.
(2003)) exhibits a 10- to 13-times selectivity for a5b3g2
receptors in benzodiazepine binding studies (Ki of 20,
16, 20, and 1.6 nM, for human a1-, a2-, a3-, and a5b3g2
receptors, respectively) and acts as a strong negative
allosteric modulator at the a5b3g2 receptor subtype
(Chambers et al., 2003). Concentration-response curves,
however, indicate that due to the exceptionally high
potency of this compound at a5b3g2 receptors and
the only 10–13-fold difference of its affinity and potency
for a5b3g2 and a1b3g2 receptors, this compound is
a5-selective at only subnanomolar concentrations.
TB21007 improved memory performance of young
rats but not of rats exhibiting age-related memory
impairment in a radial armmaze task (Koh et al., 2013).
Interestingly, in rats with age-related memory impair-
ment some poorly characterized positive allosteric modula-
tors at a5-containing receptors were effective in improving
memory performance [compound 6 in van Niel et al. (2005)
and compound 44 in Chambers et al. (2003)].
10. S44819. Recently, a substituted 8-methyl-5-[1-
benzothiophen-2-yl]-1,9-dihydro-2H-[1,3]oxazolo[4,5-
h][2,3]benzodiazepin-2-one (S44819) was claimed to be
an a5-GABAA receptor-selective antagonist competi-
tively inhibiting the action of GABA at these receptors
(Ling et al., 2015; Etherington et al., 2017) (Fig. 30).
This compound enhanced object recognition memory,
long-term potentiation, blocked tonic current mediated
by extrasynaptic a5-GABAA receptors, but had no effect
on synaptic GABAA receptors and reversed scopolamine-
induced impairment of spatial working memory in the
eight-arm radial maze. Data presented indicate, however,
that S44819 exhibited only marginal receptor subtype
selectivity. It preferentially inhibited GABA-induced cur-
rents at a5b2g2 receptors in the concentration range of
1 nM to 10 mM, with a binding constant of 221 nM.
It required about threefold higher concentrations to
inhibit a1b2g2 or a3b2g2 receptors to the same extent,
with few effects on a2b2g2 receptors up to 10 mM
concentrations (Etherington et al., 2017). This com-
pound thus selectively inhibits a5b2g2 receptors up to
only 100 nM concentration in recombinant receptors.
Nevertheless, it is the first in class compound that
uniquely acts as a relatively potent, competitive, and
selective antagonist of recombinant as well as native a5-
GABAA receptors. Its apparent selectivity in vivo cannot
be explained by its only weak selectivity for a5b3g2
receptors. Its selectivity presumably is enhanced by the
low GABA concentration acting at extrasynaptic a5bg2
receptors that can be more easily overcome by the
competitive GABA-site antagonist than the much higher
GABA concentrations acting at synaptic a1bg2 or a3bg2
receptors (Ling et al., 2015). In addition, the lowpotency of
this compound also might contribute to its selectivity,
because concentrations sufficient to inhibit signifi-
cantly synaptic receptors might not be easily achieved
in the brain.
11. XLi-093. The bivalent imidazobenzodiazepine
XLi-093 (Fig. 31) has been identified as a selective
antagonist at the benzodiazepine site of a5b3g2 GABAA
receptors. XLi-093 exhibits an affinity of 15 nM for the
benzodiazepine site of a5b3g2 GABAA receptors and a
60-fold to.100-fold lower affinity for a1-, a2-, a3-, a4-, or
a6b3g2 receptors. In electrophysiological experiments, it
has been identified as a potent antagonist of the effects
of diazepam at rat a5b3g2 GABAA receptors but not at
a1b3g2, a2b3g2, or a3b3g2 GABAA receptors (Li et al.,
2003). This compound could be a valuable tool for
Fig. 30. Chemical structure and concentration-response curves of
S44819 at various recombinant GABAA receptor subtypes, stably
expressed in HEK 293 cells and investigated by use of the fluorometric
imaging plate reader dye assay at 1.6 mMGABA (EC30–50). Recombinant
receptors were composed of the human a-subunit isoforms, together with
the rat b2S and rat g2L subunits. Modified from Etherington et al.,
Neuropharmacology, 125,353–364, Elsevier, 2017.
Fig. 29. Chemical structure and concentration-response curves of
TB21007 at various human recombinant GABAA receptor subtypes stably
expressed in L(tk-) mouse fibroblast cells and measured at GABA EC20.
Figure modified from Chambers et al. (2003) with permission of The
American Chemical Society.
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validating effects of compounds mediated via a5b3g2
GABAA receptors.
G. Compounds Preferentially Modulating a4bg2
and/or a6bg2 Receptors
GABAA receptor subtypes composed of a6bg2 (Nusser
et al., 1998) and presumably also those composed of
a4bg2 are located synaptically as well as extrasynap-
tically and thereby contribute to phasic and tonic
inhibition in the central nervous system, respectively.
Whereas a4bg2 receptors are located predominantly in
the forebrain, hippocampus, and thalamus (Benke et al.,
1997; Bencsits et al., 1999), GABAA receptors composed
of a6bg2 are predominantly located in the cerebellar
granule cells (Nusser et al., 1998; Pirker et al., 2000).
Currently, not much is known about the function of
a4bg2 or a6bg2 receptors.
1. CMD-45. The imidazobenzodiazepine CMD-45
(Fig. 32) preferentially enhances the action of GABA
at a4b3g2- and a6b3g2-containing recombinant GABAA
receptors, presumably by acting via the benzodiazepine
binding site. But this compound also modulates a1b3g2,
a2b3g2, a3b3g2, and a5b3g2 receptors to a smaller
extent. It was recently demonstrated that human airway
smooth muscle cells among GABAA receptor a subunits
express only a4 and a5 subunits (Gallos et al., 2015) and
that CMD-45 is able to significantly relax precontracted
human airway smooth muscle cells ex vivo (Yocum et al.,
2016). This seems to indicate that selective targeting of
a4-containingGABAA receptorswith inhaled ligandsmay
be a novel therapeutic pathway to treat bronchoconstric-
tion while avoiding sedative effects in the central nervous
system, which are largely mediated by a1- and possibly
also a3-containing GABAA receptors (Ralvenius et al.,
2015; Behlke et al., 2016; Yocum et al., 2016).
2. XHe-III-74. The structurally similar imidazoben-
zodiazepine XHe-III-74 (Fig. 33) exhibits a comparable
preferential efficacy for the modulation of a4b3g2 and
a6b3g2, but exhibits a weaker effect at a1b3g2
Fig. 31. Chemical structure of XLi-093 and its inhibition of the effects of diazepam at the diazepam-sensitive GABAA receptor subtypes. The
concentration-response curves show the effects of diazepam in the absence or presence of 1 mM XLi-093. Inhibition is shown by the right-shift of the
diazepam concentration-response curve. Figure modified from Li et al. (2003) with permission of The American Chemical Society.
Fig. 32. Chemical structure of CMD-45 and concentration-response
curves at various recombinant GABAA receptor subtypes from the rat
expressed in Xenopus laevis oocytes and measured at GABA EC3. *Data
for a4b3g2 and a6b3g2 are significantly different from those of a1b3g2
receptors. Figure modified from Yocum et al. (2016) with permission of
The American Thoracic Society. Copyright © 2016.
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receptors than CMD-45. Similar to CMD-45, it signifi-
cantly relaxed precontracted human airway smooth
muscle cells ex vivo and reduced respiratory system
resistance in an asthmatic mouse model in vivo (Yocum
et al., 2016). These results were confirmed and extended
by using the structurally similar XHe-III-74 ethyl ester
and XHe-III-74 acid (Forkuo et al., 2016), but the
respective concentration-response curves of the two
latter compounds were only incompletely published.
3. PZ-II-029 (Compound 6), LAU159, LAU463.
The pyrazoloquinolinone PZ-II-029 (compound 6) (Fig. 34),
as well as other structurally related compounds, are
high affinity null modulators at the benzodiazepine
binding sites of various GABAA receptor subtypes but
in addition also positively modulate a6b3g2 receptors
with low potency and exceptionally high selectivity
via the a6+b32 interface (Varagic et al., 2013a).
Recently, the structurally related LAU159 (8-chloro-2-
(3-methoxyphenyl)-2H-pyrazolo[4,3-c]quinolin-3(5H)-one)
has been demonstrated to show the highest functional
selectivity for positive modulation at a6b3g2 receptors
with nearly no residual activity at the other a125b3g2
receptors up to 10 mM concentrations (Treven et al., 2018).
PZ-II-029andLAU159, together with LAU463 (7-bromo-
2-(4-methoxyphenyl)-2,5-dihydro-3H-pyrazolo[4,3-c]-
quinolin-3-one), another a6b3g2 receptor-selective
compound, were recently used as lead compounds
for the development of a variety of deuterated a6b3g2
receptor-selective compounds with increased metabolic
stability and bioavailability (Knutson et al., 2018).
These compounds achieve 100–300 nM concentrations
in the rat brain in in vivo studies at 10 mg/kg (Knutson
et al., 2018), and due to their low potency, this is sufficient
to selectively modulate a6b3g2 receptors. The recent
demonstration that a6b3g2 receptors not only occur in
the cerebellar granule cells, the cochlea nucleus, olfactory
bulb, spinal cord, and retina (Gutiérrez et al., 1996) but
also in the trigeminal ganglia (Hayasaki et al., 2006),
striatum (Leggio et al., 2015) and in the hippocampus
(Yang et al., 2016), suggests that PZ-II-029, LAU159, and
its congeners might have interesting applications in
diseases in which this receptor subtype plays a role.
This conclusion is supported by recent reports suggest-
ing that a6-containingGABAA receptorsmay play a role
in neuropsychiatric disorders with sensorimotor gating
deficits, such as tic disorders, certain symptoms of
schizophrenia, obsessive compulsive disorders, atten-
tion deficit disorders, and Huntington’s chorea (Liao
et al., 2016; Chiou et al., 2018), as well as in depression
(Yang et al., 2016), trigeminal orofacial pain (Puri et al.,
2012; Kramer and Bellinger, 2013), trigeminal neurop-
athy, and migraine (PCT/US2016/035761).
4. (+)ROD188. Bicuculline is a competitive antago-
nist at the GABA binding site of GABAA receptors. The
bicuculline derivative (+)ROD188 (Fig. 35) is an allo-
steric modulator of GABAA receptors (Thomet et al.,
2000). Surprisingly, this compound does not interact
with the GABA binding site but competitively inhibits
[3H]Ro15-1788 binding with an IC50 value of 33.1 mM.
Electrophysiological experiments, however, indicated
that the positive allosteric modulation of GABAA recep-
tors by (+)ROD188was inhibited only partially (29%) by
Ro15-1788, indicating that most of the effects of this
compound are mediated by a so far unidentified second
Fig. 33. Chemical structure and concentration-response curves of XHe-
III-74 at various recombinant GABAA receptor subtypes from the rat
expressed in Xenopus laevis oocytes and measured at GABA EC3. *Data
for a4b3g2 and a6b3g2 are significantly different from those of a1b3g2
receptors. Figure modified from Yocum et al. (2016) with permission of
The American Thoracic Society. Copyright © 2016.
Fig. 34. Chemical structure and concentration-response curves of
PZ-II-029 (compound 6) at a variety of recombinant GABAA receptor
subtypes from the rat expressed in Xenopus laevis oocytes and
measured at GABA EC3. Figure modified from Varagic et al. (2013a).
Reprinted with permission of John Wiley & Sons, Inc.
Fig. 35. Chemical structure and concentration-response curves of (+)
ROD188 at various recombinant GABAA receptor subtypes from the rat
expressed in Xenopus laevis oocytes and measured at GABA EC5. Figure
modified from Thomet et al. (2000). Reprinted with permission of John
Wiley & Sons, Inc.
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site of action different from the benzodiazepine binding
site. Concentration response curves shown in Fig. 35
indicate that this compound preferentially modulates
a6b2g2 receptors. The in vivo effects of this compound
so far have not been investigated. In a subsequent
study, some structural analogs of (+)ROD188 also
induced a preferential modulation of a6b3g2 receptors
(Ramerstorfer et al., 2015). The absence of any direct
effects at GABAA receptors, as well as their potential
selectivity for receptor subtypes, make this compound
class suitable for drug discovery programs.
5. Amiloride. The diuretic amiloride (Fisher, 2002)
is an antagonist at a6b3g2 receptors, with no actions
at a1–5b3g2 receptors up to 30 mM concentrations
(Fig. 36). It seems to act competitively via the GABA
binding site and in addition seems to be an open channel
blocker, and the a6-subunit seems to confer higher
affinity for both sites. Amiloride inhibition was only
dependent on the a6 subunit and not influenced by the
type of b or g subunit or the presence of a d subunit in
GABAA receptors (Fisher, 2002). However, its in vivo
application is limited by the fact that amiloride does not
readily cross the blood-brain barrier, by its inhibitory
action at Na+ channels and transporters, and its
additional modulation of other transmitter receptors
(Fisher, 2002).
6. Furosemide. The diuretic furosemide (Fig. 37) is
another relatively selective antagonist at a6b2/3g2,
a6b2/3, and a6b2/3d receptors, with no interaction with
receptor subtypes containing other a subunits up to
3 mM concentrations. But furosemide does not interact
with b1-containing receptors (Korpi et al., 1995; Wafford
et al., 1996; Korpi and Lüddens, 1997) and presumably
interacts with a binding site within the transmembrane
domain of a6 subunits (Thompson et al., 1999), which is
different from that of amiloride (Fisher, 2002). As with
amiloride, its in vivo application is limited due to its
diuretic properties.
H. Benzodiazepine Site Antagonist Actions
Currently, there are only a few compounds that are
antagonists (null modulators) at the benzodiazepine
site of GABAA receptor subtypes. b-CCt (Fig. 4, see
section V.B.4) is an antagonist at a1, and less avidly, at
a2 receptors, but is a weak positive modulator at a3 and
a4 and a negativemodulator ata5 receptors (June et al.,
2003; Yin et al., 2010). Flumazenil (Ro15-1788) (Figs. 4
and 5, see section V.B.5), is an antagonist ata1 receptors
only, but a positive allosteric modulator at a2-, a3-, a4-,
and a6-containing receptors and a weakly negative
modulator of a5b3g2 receptors (Ramerstorfer et al.,
2010). The bivalent imidazobenzodiazepine XLi-093
(Fig. 31, see section V. F. 11) is a selective antagonist
at the benzodiazepine site of a5b3g2 GABAA receptors
(Li et al., 2003), but unfortunately its actions at a4bg2
and a6bg2 receptors have not been investigated. Since
imidazobenzodiazepines usually can bind to the benzo-
diazepine site of a4bg2 and a6bg2 receptors, some
actions of XLi-093 at these receptors can be expected.
PZ-II-029 (Fig. 34, see section V.G.3) or LAU159 is a
high affinity antagonist at the benzodiazepine site of
a1–6bg2 receptors, but low potency positivemodulators
of a6bg2 receptors by an additional action via the a+b2
interface of GABAA receptors (Varagic et al., 2013a).
It could be concluded that these compounds on
systemic or local application are only silent at receptors
for which they are null modulators, but in addition
modulate other receptor subtypes according to their
respective potency and efficacy. In addition, all these
compounds are able to antagonize the actions of strongly
Fig. 36. Chemical structure and concentration-response curves of amiloride showing its inhibition of the currents elicited by 1 (a6), 3 (a4,a5), or 10 mM
(a1, a2, a3) GABA at various rat GABAA receptor subtypes recombinantly expressed in mouse fibroblast cell line L929. Figure modified from Fisher (2002).
Fig. 37. Chemical structure and concentration-response curves of
furosemide showing its inhibition of a GABA EC50 response at human
GABAA receptors expressed in Xenopus laevis oocytes. Figure modified
from Thompson et al. (1999).
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positive or negative allosteric modulators at the benzo-
diazepine site, at all receptor subtypes at which they
exhibit a null modulatory, weakly positive, or weakly
negative allosteric modulation.
But null modulators at the benzodiazepine site also
may exert additional actions in the brain. More than
30 years ago, in addition to other compounds, a peptide
was identified in the brain that is able to inhibit the
binding of diazepam to brain membranes (diazepam
binding inhibitor, DBI (Costa and Guidotti, 1985). DBI
and other compoundswith similar actionsmight thus be
endogenous modulators of GABAA receptors acting via
the benzodiazepine site. Recently, new evidence for the
existence and function of endogenous ligands for the
benzodiazepine binding site has been accumulated
(Möhler, 2014), and it seems clear now that endozepines,
such as DBI or octadecaneuropeptide, might negatively or
positively modulate the function of GABAA receptors via
the benzodiazepine site and by thatmodulate, for instance,
neurogenesis or thalamic oscillations, respectively. Flu-
mazenil seems to be able to inhibit the actions of these
endogenousmodulators (Möhler, 2014), and similar effects
can also be expected from other benzodiazepine site null
modulators. Thus antagonists at the benzodiazepine site
are not necessarily silent but might interfere with the
actions of endogenous modulators in the brain, and this
could contribute to their spectrum of action in vivo (Hulse
et al., 2015). Because the receptor subtype selectivity of
endogenous modulators of the benzodiazepine site of
GABAA receptors currently is not known, the receptor
subtype(s) mediating the behavioral action of a benzodi-
azepine site antagonist via blockade of endogenous mod-
ulators cannot be delineated. In addition, it is not possible
to distinguish between effects of benzodiazepine site
antagonists elicited by their direct modulation of some
GABAA receptor subtypes and effects elicited by blockade
of endogenous ligands.
I. Compounds Claimed to Selectively Modulate b1-
containing GABAA Receptors
The majority of GABAA receptors is composed of two
a, two b, and one g or one d subunit (Barnard et al., 1998;
Olsen and Sieghart, 2008), and there is also evidence for
the existence of receptors composed of ab subunits in
the brain (Mortensen and Smart, 2006; Olsen and
Sieghart, 2008). The latter receptorsmight be composed
of two a and three b subunits (Tretter et al., 1997;
Baumann et al., 2001), but different stoichiometries
seem to be possible (Im et al., 1995; Boileau et al., 2005;
Che Has et al., 2016). Receptors containing «, u, or p
subunits also seem to contain b subunits (Olsen and
Sieghart, 2008). Depending on the type of b subunit
present in receptors, their regional, cellular, and sub-
cellular distribution, as well as their function in the
brain, might be different. Drugs that are able to
selectively modulate receptors containing a specific b
subunit only will thus exhibit more specific properties
and less unwanted effects than those that cannot differ-
entiate between receptors containing different b subunits.
In addition, there is ample evidence for the existence of
two different a and/or two different b subunits in native
GABAA receptors (Jechlinger et al., 1998; Benke et al.,
2004; Olsen and Sieghart, 2008). Depending on the types
of a and b subunits within the receptors, their stoichiom-
etry, and their subunit arrangement, the receptors con-
tain distinct subunit interfaces and thus, exhibit distinct
pharmacological properties that might allow for selec-
tively targeting the respective receptor subtypes (CheHas
et al., 2016). However, the pharmacology of receptor
subtypes containing two different a or b subunits so far
has not been sufficiently investigated. Depending on their
regional, cellular, and subcellular location in the brain,
they contribute to different types of behavior (Ralvenius
et al., 2015). It thus can be expected that the behavioral
selectivity of compounds can be increased if they not only
can distinguish between different a but also between
different b subunits or even between receptors containing
different a and b subunit combinations. First evidence for
this assumption is provided by the in vivo actions of
compounds that can distinguish between receptors con-
taining different types of b subunits.
1. Salicylidene Salicylhydrazide. By screening ap-
proximately 10,000 compounds from a structurally di-
verse screening library for their activity on a2b1g1u,
a3b3g2s, and a4b3g2s GABAA receptors at a single
concentration (8 mM) and using a high-throughput
voltage/ion probe reader assay, salicylidene salicylhy-
drazide (Fig. 38), was identified as a potent selective
inhibitor of a2b1g1u, with amaximum inhibition of 56%
and an IC50 of about 32 nM (Thompson et al., 2004). By
using patch-clamp electrophysiological techniques, it
was then demonstrated that the compound in a limited
set of receptor subtypes was selective for the b1 subunit.
The extent of inhibition was modulated by a1 and a2,
g1, and g2, but was not dependent on the presence of
u subunits. Salicylidene salicylhydrazide produced incom-
plete inhibition on all b1-containing subtypes investigated
and, hence, seemednot to actwithin the ion channel but via
a so far unidentified binding site (Thompson et al., 2004).
Although there are only limited biologic data with salicy-
lidene salicylhydrazide, it is a known chelator ofmetal ions
and in vitro has comparable cytotoxicity to cisplatin.
In addition, this compound also exhibited poor in vivo
pharmacokinetics and thus seems to be of limited use
for the investigation of the function of b1 subunit-
containing receptors (Thompson et al., 2004).
2. Fragrant Dioxane Derivatives. By screening sev-
eral libraries of odorants, fragrant (1,3)-dioxane deriv-
atives were identified (Fig. 38) that enhance the action
of GABA with six times higher potency at b1 subunit-
containing compared with the b2 or b3 subunit-
containing GABAA receptors (Sergeeva et al., 2010).
In the limited set of recombinant receptors investigated,
the effects of the fragrant dioxane derivatives depended
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only on the type of b subunit, were independent of the
g subunit, and obviously were similar in a1- or a2-
containing receptors. These compounds act via a so far
unidentified binding site at GABAA receptors and up to
a 10 mM concentration selectively modulated a1b1g2
receptors. With the help of these compounds, b1 subunits
were identified in synapses thatmodulatewake-promoting
histaminergic neurons in the posterior hypothalamus,
indicating that b1-containing receptors might regulate
wakefulness and sleep (Sergeeva et al., 2010).
3. Pyrazoloquinolinones. Pyrazoloquinolinones, such
as CGS 9895 or PZ-II-029 (compound 6; see section V.G.3)
in many cases are high-affinity antagonists (null modula-
tors) at the benzodiazepine binding site (a+g22 interface)
Fig. 38. Compounds selective for b1- or b2/3-containing GABAA receptors.
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of GABAΑ receptors and exert their low-potency allosteric
modulatory action of GABAA receptors via an additional
binding site at the a+b2 interface (Ramerstorfer et al.,
2011; Varagic et al., 2013b). Since both a and b subunits
contribute to the latter interface, the action of these
compounds is strongly dependent on the a as well as the
b subunit type. Whereas CGS 9895 and PZ-II-029 prefer-
entially modulate GABAA receptors containing b2 or b3
subunits, some other pyrazoloquinolinones, such as PZ-II-
028 (compound 11 of Varagic et al., 2013b), as well as some
structural analogs thereof, preferentially or exclusively
(DCBS96, Fig. 38) modulate GABAA receptors containing
b1 subunits (Simeone et al., 2017). Unfortunately, how-
ever, the so far investigated compounds show only limited
a selectivity and, thus, can only be used for investigating
the effects of b1 subunit-containing receptors irrespective
of the associated a subunit type.
J. Compounds Claimed to Selectively Modulate
b2/3-containing GABAA Receptors
The majority of GABAA receptors contain b2 and/or
b3 subunits (Sieghart and Sperk, 2002), and so far, no
compounds could be identified that can distinguish
between receptors containing one or the other b subunit
type, with the possible exception of Thio-THIP (Fig. 39;
see section V.K.1.c). However, molecular genetic tech-
niques provided evidence that b2- or b3-containing
GABAA receptors contribute to distinct behavioral
actions of anesthetics.
1. Loreclezole, Etomidate, and Others. A variety
of compounds have been claimed to be b2/3 selective
(Fig. 38), such as the anticonvulsant loreclezole (Wafford
et al., 1994; Wingrove et al., 1994), the intravenous
general anesthetics etomidate (Belelli et al., 1997;
Hill-Venning et al., 1997) or E-6375 (Pau et al., 2003),
the inhalation anesthetic isoflurane (Li et al., 2010),
some g-butyrolactones (El Hadri et al., 2002), mefe-
namic acid (Halliwell et al., 1999) and certain other
nonsteroidal anti-inflammatory agents (Smith et al.,
2004), the anxiolytic and anticonvulsant tracazolate
(Thompson et al., 2002b; Smith et al., 2004), the anticon-
vulsant sesquiterpenoid valerenic acid and its derivatives
(Khom et al., 2007, 2016), furosemide (Fig. 37) (Thompson
et al., 1999), or the anxiolytic-like flavanoid Fa131
(Fig. 16) (Fernandez et al., 2012). All of these compounds,
with the exception of etomidate, for which binding sites
have been identified in the two b+a2 transmembrane
interfaces of a1b2/3g2 receptors (Feng and Forman,
2018), are allosteric modulators at GABAA receptors
acting via so far unidentified binding sites. But actually
they are not b2/3 selective at all, and only preferentially
modulate b2/3-containing GABAA receptors. In addition,
they also modulate b1-containing receptors and some-
times to a quite significant extent (Gee et al., 2010).
Loreclezole was the first one of these compounds
identified, and it was demonstrated that the preferen-
tial interaction of loreclezole with b2- or b3-containing
GABAA receptors depended on a single asparagine resi-
due in the second transmembrane domain of b subunits
(b2Asn289 or b3Asn290, when numbered including the
signal peptide, or Asn265 in the b2 and b3 subunit,
numbering of the mature subunits) that was different
from the serine at the homologous position inb1 subunits
(Wingrove et al., 1994). Since the b2/3 selectivity of all
the above mentioned compounds depended on the same
amino acid residues, all these compounds were claimed
to act via this “loreclezole binding site.” These residues,
however, are not necessarily near the respective binding
sites but might be involved in the signal transduction of
the drug effects to the ion channel.
Interestingly, the flavanoid Fa173 (Fig. 38) was dem-
onstrated to be an antagonist of the positive modulatory
actions of the flavanoid Fa131 (Fig. 16; see section V.D.9),
as well as of etomidate (Fig. 38), loreclezole (Fig. 38), and
the GABA-potentiating effects induced by high, but not
low, concentrations of diazepam at a1b2 and a1b2g2L
receptors. The action of all these compounds could be
reduced by the point mutation b2Asn265Ser (Fernandez
et al., 2012). These results reinforce the idea that these
compounds either share their binding pocket or activation
domains. Fa173, however, did not block the modulatory
actions of the neuroactive steroid 5a-pregnan-3a-ol-
20-one, the barbiturate thiopental, and the anesthetic
propofol at GABA-induced currents, suggesting that
these compounds act via a binding site different from
that of loreclezole and etomidate (Fernandez et al., 2012).
Further investigations using this antagonistic compound
might answer the question whether the effects of Fa173
occur through competition for the loreclezole, etomidate,
flavanoid site (loreclezole site), or via another allosteric
site, blocking the signal transduction of these compounds.
In any case, Fa173 represents a lead compound in the
development of novel antagonists at GABAA receptors
(Fernandez et al., 2012).
The convulsant b-carboline DMCM (Fig. 38) is a
benzodiazepine site ligand with negative allosteric mod-
ulatory actions at most GABAA receptor subtypes below
1 mM concentration. At higher concentrations, this
compound turns into a positive allosteric modulator,
suggesting interaction with a second binding site at
GABAA receptors (Ramerstorfer et al., 2010). At a6b3g2
receptors, however, DMCM does not exhibit a negative
modulation of GABA-induced currents and is a positive
allosteric modulator above 100 nM concentrations
(Ramerstorfer et al., 2010). This positive allosteric
modulation by .1 mM DMCM at all receptor subtypes
investigated was not inhibited by the benzodiazepine
site antagonist Ro15-1788, was only observed at b2-
or b3-containing receptors and was dependent on the
presence of b3Asn290 (numbering including signal
peptide) (Stevenson et al., 1995). Therefore, DMCM
not only interacts with the benzodiazepine site at
nanomolar concentrations but also with the “loreclezole
site” at .1 mM concentrations.
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2. Etifoxine and Polyacetylene Compounds. In con-
trast to the compounds mentioned above, the anxiolytic-
like and anticonvulsant etifoxine (Fig. 38) (Schlichter
et al., 2000; Hamon et al., 2003) or some polyacetylene
compounds (Baur et al., 2005) might mediate their
preferentialmodulation ofb2- orb3-containing receptors
via an unidentified site different from the “loreclezole
site.” Interestingly, etifoxine might elicit its anxiolytic-
like action at least partially via an additional interaction
with the so called “peripheral benzodiazepine receptor,”
now called the 18-kDa translocator protein (TSPO) that
seems to be involved in the regulation of neurosteroid
synthesis and is also discussed as a target for anxiolytic
drugs (Costa et al., 2012; Nothdurfter et al., 2012).
3. b2/3-Selective Enaminones (Compound 2-261).
Empirical observations of the b2/3 selective compounds
loreclezole, mefenamic acid, tracazolate, and etifoxine
(section V.J.1) in both animals and humans provided
anecdotal evidence for the possibility that the degree of
activation of b1 subunit-containing GABAA receptors
may contribute to their sedative/ataxic properties
(Gee et al., 2010). Based on this hypothesis, several
enaminones were investigated for their positive alloste-
ric modulation of a1b1g2 or a1b2g2 GABAA receptors.
These compounds allosterically modulate GABAA recep-
tors via a so far unidentified binding site and compared
with other b2/3-selective compounds, such as loreclezole,
tracazolate, or etomidate, exert a dramatically reduced
maximal efficacy at a1b1g2 over a1b2g2 GABAA recep-
tors (Gee et al., 2010). GABA-dependent modulation
by the prototypic compound 2-261 (Fig. 38) at b2/3-
containing receptors did not appear to be strongly de-
pendent on the type ofa subunits. This compound showed
equivalentmaximalmodulation at a1-, a2-, or a3b2/3g2
receptors. Compound 2-261 produced anxiolytic-like
actions with reduced ataxic or sleep-inducing effects
(Gee et al., 2010; Yanovsky et al., 2012), and the degree
of sedation/ataxia induced by different enaminones or
other b2/3-selective compounds (section V.J.1) corre-
lated with their activity at a1b1g2 receptors. Com-
pounds with high efficacy at b1-containing GABAA
receptors induced rotarod failures, whereas those with
low activity at these receptors did not. In addition, it
was demonstrated that compounds that reach brain
levels associated with .47% stimulation of the a1b1g2
receptor elicit rotarod deficits regardless of the potency of
the compound (Gee et al., 2010).
4. Function of b2 or b3 Subunit-containing GABAA
Receptors. Given the relatively low selectivity of the
b2/3-selective compounds, their inability to distinguish
between b2- or b3-containing receptors, their differen-
tial interaction with various GABAA receptor subtypes,
and their widely different effects in vivo, these com-
pounds could not be used to delineate a possible function
of b2- or b3-containing receptors in the brain. Neverthe-
less, using mice harboring point mutated b2 or b3 sub-
units that drastically reduced the effects of etomidate,
loreclezole, or of the inhalation anesthetic isoflurane,
either in b2 (b2Asn265Ser)- (Reynolds et al., 2003;
Groves et al., 2006) or b3 (b3Asn265Meth)- (Jurd et al.,
2003; Lambert et al., 2005) containing receptors, some
attribution of the in vivo functions of b2 or b3 subunit-
containing receptors was still possible. The anticonvulsant
effects of loreclezole seem at least partially to be mediated
via b2-containing receptors (Reynolds et al., 2003; Belelli
et al., 2005; Zeller et al., 2005; Groves et al., 2006). The
hypothermic and cardiac depressant effects of etomi-
date seem to be predominantly mediated by b2-contain-
ing receptors (Zeller et al., 2005), suggesting that
avoiding b2-containing receptormodulation should lead
to an improved recovery after anesthesia (Cirone et al.,
2004). The sedative action of etomidate (action on
locomotor activity) is mediated by b2-containing
GABAA receptors (Reynolds et al., 2003). The hypnotic
actions of etomidate and propofol (loss of righting reflex)
seem to be mediated via both b3 and b2 receptors (Jurd
et al., 2003; Reynolds et al., 2003; Zeller et al., 2005). In
contrast, both the immobilizing action of etomidate and
of propofol and their induction of respiratory depression
seem to be mediated via b3-containing receptors (Jurd
et al., 2003; Reynolds et al., 2003; Zeller et al., 2005,
2007). The anterograde amnesic action of propofol is
independent of b3-containing receptors (Zeller et al.,
2007). The type(s) of a subunits present in receptors
mediating the individual effects of anesthetics, how-
ever, could not be identified by these experiments. In
addition, these experiments could not answer the
question whether the respective receptors were of the
ab, abg,abd,ab« type orwhether they contained g1, g2,
or g3 subunits.
K. Compounds Claimed To Modulate Selectively
d-Containing GABAA Receptors
GABAA receptors containing d subunits seem to be
exclusively located extrasynaptically (Nusser et al.,
1998) and contribute to the tonic inhibition of neurons
in the brain that modulates both cell and network
behavior (Farrant and Nusser, 2005). They seem to be
dynamically expressed during ovarian cycle, stress, and
puberty (Shen et al., 2017), and evidence has been
accumulated that drugs selectively modulating d-con-
taining GABAA receptors might be beneficial for a
variety of human disorders (Brickley and Mody, 2012).
However, studies with concatenated a1b3d GABAA
receptors have indicated that there might be several
possibilities for the incorporation of a d subunit in
recombinant receptors (Kaur et al., 2009; Eaton et al.,
2014; Botzolakis et al., 2016; Wongsamitkul et al., 2016).
Depending on the subunit stoichiometry and arrange-
ment, these receptors exhibit distinct properties. This
conclusion is supported by the finding that nonconcaten-
ated a6bd (Hadley and Amin, 2007) and a4b1/3d (Karim
et al., 2012b) receptors can be activated by GABA with a
nanomolar and a micromolar potency and that the latter
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receptor might form a novel GABA-binding site at the d
subunit interface (Karim et al., 2012b). The mixture of
recombinant receptors formed will thus determine the
pharmacological properties measured (Hartiadi et al.,
2016). If receptors with distinct stoichiometry and sub-
unit arrangement are also present in the brain, they
represent novel receptor subtypes that, depending on
their regional, cellular, and subcellular distribution, will
modulate distinct brain functions.
1. g-Aminobutyric Acid Site Ligands. GABA and
orthosteric GABA-site agonists, such as muscimol,
isoguvacine, or THIP, exhibit up to 100-fold difference
in their potency and efficacy for activation of various
GABAA receptor subtypes (Fig. 39A) (Ebert et al., 1994;
Ducic et al., 1995; Frølund et al., 2002; Mortensen et al.,
2012; Karim et al., 2013).
a. THIP (gaboxadol). The GABA agonist THIP
(gaboxadol, Fig. 39A) has been shown to be devoid of
the neurotoxic properties of muscimol and, in contrast
to muscimol, is metabolically stable. It is less potent
than GABA but approximately 10 times more potent at
d-containing receptors than at g2S-containing receptors
(Brown et al., 2002; Frølund et al., 2002) and in contrast
to GABA that is a partial agonist at d-containing
receptors (Bianchi and Macdonald, 2003; Meera et al.,
2011), it is a full agonist at these receptors and thus
elicits a markedly larger response than GABA. This
view, however, was recently challenged by demonstrat-
ing that THIP at a6b3d receptors exhibits a high
potency but low efficacy, whereas at the contaminating
a6b3 receptors it exhibits a low potency high efficacy
modulation (Meera et al., 2011). The previously ob-
served high efficacy modulation by THIP of a6b3d
receptors might thus have been mediated by simulta-
neously formed a6b3 receptors, which not only might be
present in recombinant expression systems but also in
the brain. Due to its sleep-inducing and analgesic action
(Krogsgaard-Larsen et al., 2004; Wafford and Ebert,
2006), gaboxadol was developed as a hypnotic drug with
no tolerance to sleep EEG and sedative effects after
repeated daily dosing (Ebert et al., 2008), but its clinical
development was abandoned due to safety concerns. In
any case, this compound provided some insight on the
role of d-containing GABAA receptors in sedation and
sleep (Krogsgaard-Larsen et al., 2004; Herd et al.,
2009). It has to be kept in mind, however, that THIP
is also an antagonist at r-containing GABAA receptors
(Chebib, 2004). The interpretation of the in vivo results
of this compound may therefore be more equivocal than
previously assumed.
b. Thio-4-PIOL. The GABA site agonist Thio-4-PIOL
(Fig. 39A) displayed substantial partial agonist activity
of up to 30% relative to the effect of GABA at the human
extrasynaptic GABAA receptor subtypes composed of
a5b3g2s, a4b3d, and a6b3d, and somewhat lower effica-
cies (4%–12%) at the corresponding a5b2g2s, a4b2d, and
a6b2d subtypes (Hoestgaard-Jensen et al., 2013). In
contrast, it was an antagonist at the synaptic GABAA
receptors composed of a1b2,3g2S, a2b2,3g2S, and
a3b2,3g2S (maximal responses of 0%–4% of the GABA
current). Thio-4-PIOL thus possibly could be used for
exploring the physiologic roles of native synaptic and
extrasynaptic GABAA receptors (Hoestgaard-Jensen
et al., 2013).
c. Thio-THIP. The GABA site agonist Thio-THIP
(Fig. 39A) displayed weak antagonistic activity at
a1,2,5b2,3g2s and r1 receptors and partial agonism
at a6b2,3d receptors. It also exhibited a pronounced
agonism at a4b1d and a4b3d and a negligible activity at
a4b2d receptors. Thio-THIP is thus the first published
ligand capable of discriminating between b2- and b3-
containing receptor subtypes and could be a valuable
tool for the exploration of native a4bdGABAA receptors
(Hoestgaard-Jensen et al., 2014).
d. GABA site antagonists. While the potency of GABA
site agonists and modulators of GABAA receptors varies
with subunit composition, the potency of GABA site
antagonists such as bicuculline, SR95531 (Fig. 39B), and
others is largely independent of receptor subunit compo-
sition (Lüddens and Korpi, 1995; Ebert et al., 1997;
Frølund et al., 2002; Johnston, 2013).
Fig. 39. GABA-site ligands. (A) GABA-site agonists at abg receptors. (B)
GABA-site antagonists at abg receptors. (C) GABA-site agonists and
antagonists at r-containing receptors.
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Recently, however, the compound S44819 was claimed
to be an orthosteric, competitive, a5-GABAA receptor-
selective antagonist (Ling et al., 2015; Etherington et al.,
2017; see Fig. 30, section V.F.10). Although this compound
exhibited only an about threefold selectivity for a5b3g2
over a1b3g2 or a3b3g2 receptors when recombinantly
expressed, its selectivity in vivo is enhanced due to the low
extrasynaptic GABA concentrations at a5b3g2 receptors,
which can be more easily overcome by this antagonist
than thehigh synapticGABAconcentrations ata1b3g2 or
a3b3g2 receptors (Ling et al., 2015; see section V.F.10). In
addition, the low potency of this compound also might
have contributed to its selectivity in vivo, because concen-
trations sufficient to inhibit significantly fully saturated
synaptic receptors might not be easily achieved in the
brain. So far the action of S44819at d-containing receptors
has not been investigated. It can be assumed, however,
that it also will preferentially inhibit a5bd over other
d-containing receptors.
In addition, the diuretic amiloride (Fig. 36; see
section V.G.5) is a relative selective antagonist at
a6b123g123, or a6b3d receptors and seems to medi-
ate its action primarily as a competitive antagonist of
the GABA binding site of these receptors (Fisher, 2002).
2. Neurosteroids and Tracazolate. The anxiolytic,
sedative, and anticonvulsant neurosteroids seem to act
via several neurosteroid binding sites in the trans-
membrane domain of GABAA receptors that still have
not been unequivocally identified and might differ in
different receptor subtypes (Seljeset et al., 2015;
Laverty et al., 2017). They are able to modulate
d-containing receptors to a much stronger extent than
other GABAA receptors presumably by shifting the
physiologic GABA-induced partial agonist activation
of d-containing GABAA receptors from low-to high-
efficacy gating patterns (Belelli et al., 2002; Bianchi
and Macdonald, 2003; but see also Meera et al., 2011).
The same seems to hold true for the nonsedative
anxiolytic-like and anticonvulsant pyrazolopyridine
tracazolate (Fig. 38) that seems to act via a so far
unidentified binding site at GABAA receptors (Thompson
et al., 2002b; Zheleznova et al., 2008). This compound,
however, is also interacting with adenosine receptors
and phosphodiesterases (Thompson et al., 2002b).
3. Ketamine. The chiral arylcyclohexylamine (Fig. 40)
is a dissociative anesthetic capable of inducing analge-
sia, psychomimetic behavior, and a catatonic state of
unconsciousness. It noncompetitively inhibits NMDA
receptors, and at anesthetically relevant concentrations
is also a positive allosteric modulator at GABAA recep-
tors. Up to concentrations of 20 mM ketamine exhibits
some selectivity for a6b2d- and a6b3d-containing re-
ceptors compared with a limited set of other GABAA
receptor subtypes (a1b2g2, a1b2, a1b2d, a4b2g2,
a4b2d, a6b2g2) (Hevers et al., 2008). At higher concen-
trations, ketamine directly activates both a6b2d- and
a6b3d-receptor subtypes.
4. DS2. The imidazopyridine DS2 (Fig. 41) is a rela-
tively selective positive modulator of d-containing recep-
tors (Wafford et al., 2009). It exhibits weak effects at
a1b2g2, a2b2g2, a3b2g2, and a5b2g2 receptors, but
strongly modulates a4b1d, a4b2d, a4b3d, and a6b2d
receptors (Jensen et al., 2013). It interacts with a novel
binding site at GABAA receptors that so far has not been
identified. The bar graph in Fig. 41 shows the extremely
strong potentiation of GABA-induced currents by this
compound at d-containing GABAA receptors. Unfortu-
nately, however, in vivo experiments with this compound
are hampered because of its very poor brain penetration.
Nevertheless, this compound can be used in slice experi-
ments to clarify the function of d-containing GABAA
receptors (Ye et al., 2013).
5. Methaqualone. The sedative-hypnotic and recre-
ational drug methaqualone (Fig. 42) was demonstrated
to be a positive allosteric modulator at human
a1,2,3,5b2,3g2s GABAA receptors, whereas it displayed
highly diverse functionalities at the a4,6b1,2,3dGABAA
receptor subtypes, ranging from inactivity (a4b1d)
Fig. 40. Chemical structure of ketamine and bar graphs representing the
average of ketamine-dependent potentiation (at 10, 20, 50, and 100 mM
ketamine) of the indicated rat recombinant receptors at GABA EC3.
Figure modified from Hevers et al. (2008) with permission of the Society
of Neuroscience.
Fig. 41. Chemical structure of DS2 and bar graphs indicating the
modulation by 10 mM DS2 of the indicated human recombinant receptor
subtypes expressed in Xenopus laevis oocytes and stimulated by GABA
EC5–20 (for a1–5b2g2) or GABA EC20–50 for a1b2d and a4b1–3d and
a6b2d relative to the action of the agonist GABA (rel.AG). In addition,
EC50 values of DS2 were determined from full concentration-response
curves and given below the indicated receptor subtypes. Unfortunately,
most of these full concentration-response curves were not published.
Figure modified from Jensen et al. (2013). Reprinted with permission of
John Wiley & Sons, Inc.
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through negative (a6b1d) or positive allosteric modula-
tion (a4b2d, a6b2,3d) to extremely strong effects at
a4b3d (Hammer et al., 2015). Methaqualone was pro-
posed to interact with the transmembrane b+a2 in-
terface, possibly targeting a site overlapping with that
of the general anesthetic etomidate. Methaqualone
exhibited negligible activities at numerous neurotrans-
mitter receptors and transporters, suggesting that it is
a selective GABAA receptor modulator. In addition, the
doses producing significant in vivo effects in assays for
locomotion and anticonvulsant activity correlated fairly
well with its potencies as a modulator of recombinant
GABAA receptors (Hammer et al., 2015).
L. Compounds Modulating g1- or g3-Containing
GABAA Receptors
GABAA receptors containing g2 subunits are the
major GABAA receptor subtypes in the brain. Sixty to
seventy percent of all GABAA receptors contain this
subunit (Sieghart and Sperk, 2002), and most of the
compounds discussed so far exert their actions at least
partially via these receptors. GABAA receptors contain-
ing g1 or g3 subunits have not been investigated as
extensively as those containing g2 subunits, presum-
ably because of their low abundance in the brain. Three
to eleven percent or 3%–14% of all GABAA receptors
contain g1 or g3 subunits, respectively (Pirker et al., 2000;
Sieghart and Sperk, 2002). The g1 subunit is absent or
only weakly expressed in most rat brain regions but is
relatively enriched in the basal ganglia, the septal and
basal forebrain region, the amygdala, in some thalamic
and hypothalamic areas, cerebellum, pons, and medulla.
The g3 subunit is weakly expressed and diffusely distrib-
uted all over the rat brain (Wisden et al., 1992; Pirker
et al., 2000). Nevertheless, despite their relatively low
abundance, these receptors might have important regu-
latory functions in the brain. In the absence of any
information on their abundance and regional and cellular
distribution in the human brain, their possible impor-
tance for regulating the function of the human central
nervous system cannot be estimated. Since these recep-
tors contain most (if not all) drug binding sites that are
also present on g2-containing receptors, they can also be
modulated by most, if not all the compounds modulating
receptors containing g2 subunits. In any case, g1-contain-
ing (Ymer et al., 1990; Puia et al., 1991; Wafford et al.,
1993; Belelli et al., 2002; Khom et al., 2006) or g3-con-
taining receptors (Knoflach et al., 1991; Herb et al., 1992;
Graham et al., 1996; Sur et al., 1998; Davies et al., 2000;
Lippa et al., 2005) also have a benzodiazepine binding site
and thus can bemodulated by benzodiazepine site ligands
(Sieghart, 1995), although in most cases with a lower
potency and/or efficacy as judged by the limited number of
compounds investigated. So far, no compounds have been
identified that selectively modulate g1 or g3 subunit-
containing receptors.
M. Compounds Modulating «-, u-, or p-Containing
GABAA Receptors
Not much is known about «-containing GABAA
receptors (Davies et al., 1997a, 2001; Whiting et al.,
1997; Neelands et al., 1999; Moragues et al., 2000, 2002,
2003; Thompson et al., 2002a; Maksay et al., 2003;
Sergeeva et al., 2005; Bollan et al., 2008) and even less
about GABAA receptors containing u (Bonnert et al.,
1999; Sinkkonen et al., 2000; Moragues et al., 2002;
Ranna et al., 2006) or p subunits (Hedblom andKirkness,
1997; Neelands and Macdonald, 1999; Jin et al., 2005).
The overall abundance of these receptors in the brain so
far has not been investigated. The cDNA sequences of the
« and u subunitswere divergent inmouse, rat, and human
tissues (Sinkkonen et al., 2000; Davies et al., 2002;
Thompson et al., 2002a), and due to discrepant data in
the literature, many researchers might have hesitated to
investigate receptors containing these subunits. Recep-
tors containing «, u, or p subunits are present in
peripheral tissues as well as in the brain (Sieghart
and Sperk, 2002), as indicated by in situ hybridization
studies. The « subunit has been demonstrated to be
expressed by neurons located in septal and preoptic
areas as well as in various hypothalamic nuclei, amyg-
dala and thalamus, and the mRNA was also detected in
major neuronal groups with broad-range influence,
such as the cholinergic (basal nucleus), dopaminergic
(substantia nigra compacta), serotonergic (raphe nu-
clei), and noradrenergic (locus coeruleus systems) neu-
rons (Moragues et al., 2000, 2002, 2003). The u subunit
showed strikingly overlapping expression patterns with
« subunits throughout the brain. The p subunit was
detected in several peripheral human tissues as well
as in the brain (hippocampus and temporal cortex)
(Hedblom and Kirkness, 1997; Neelands and Macdon-
ald, 1999). But so far no study investigating the detailed
regional distribution of p subunits in the brain has been
published.
«, u, and p subunits can combine with other GABAA
receptor subunits in recombinant expression systems,
resulting in receptors with unique subunit composition
and pharmacological properties. As with d subunits, «
Fig. 42. Chemical structure and concentration-response curves of
methaqualone at various human GABAA receptors expressed in Xenopus
oocytes, measured at GABA EC10. Data were normalized to the maximal
response elicited by GABA on each oocyte. Figure modified from Hammer
et al. (2015).
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subunits might form receptors that differ in their sub-
unit stoichiometry and arrangement (Wagner et al.,
2005; Ranna et al., 2006; Bollan et al., 2008). However,
the actual subunit composition of native GABAΑ recep-
tors containing these subunits is not known and has not
been extensively investigated due to a lack of subunit-
specific antibodies for immunoprecipitation experiments.
No compounds have been identified yet that selectively
modulate these receptors.
N. Compounds Modulating r-Containing
GABAA Receptors
r-Containing receptors form homo-oligomers or hetero-
oligomers with other r subunits or possibly even with
some other GABAA receptor or glycine receptor subunits
(Qian and Ripps, 1999; Pan et al., 2000; Hartmann et al.,
2004;Milligan et al., 2004; Frazao et al., 2007). Originally,
r-containing receptors were named GABAC receptors
because of some differences in their pharmacology com-
pared with GABAA receptors (Chebib, 2004; Martínez-
Delgado et al., 2010; Ng et al., 2011; Naffaa et al., 2017).
Due to the sequence homology of r-subunits with other
GABAA receptor subunits as well as the structural
homology of r-containing receptors with abg GABAA
receptors, the International Union of Pharmacology
nomenclature commission decided that r-containing
receptors belong to the GABAA receptor family and
should be classified as such (Barnard et al., 1998; Olsen
and Sieghart, 2008). This is even more justified consid-
ering homo-oligomeric b3 receptors. These receptors
share many pharmacological properties with ab or
abg2 receptors (Slany et al., 1995; Zezula et al., 1996;
Davies et al., 1997b; Wooltorton et al., 1997), but are
activated by histamine and not by GABA or muscimol
(Saras et al., 2008; Hoerbelt et al., 2016). A distinct
pharmacology thus cannot be used as a criterion for a
distinct receptor nomenclature (Barnard et al., 1998;
Olsen and Sieghart, 2008). Although homo-oligomeric
b3 receptors so far have not been identified in the brain
due to the lack of selective ligands and the abundant
expression of b3 subunits as constituents of ab3g2
GABAA receptors, their easy formation in recombinant
expression systems that recently culminated in the first
crystal structure of a GABAA receptor subtype (Miller
and Aricescu, 2014), indicates that these receptors prob-
ably are expressed also in the brain.
GABAA receptors containing r subunits originally
were identified in the retina (Cutting et al., 1991; Enz
et al., 1996; Enz and Cutting, 1998), but later were also
identified inmany areas of themammalian brain (Boue-
Grabot et al., 1998; Wegelius et al., 1998; López-Chávez
et al., 2005; Martínez-Delgado et al., 2010; Naffaa et al.,
2017). However, the overall abundance of these sub-
units relative to other GABAA receptor subunits so
far has not been investigated. The localization of the
various r-containing GABAA receptors, as well as
knockout and pharmacological studies, indicate that
these receptors might play a role in visual processing
andmyopia development, olfactory senses, learning and
memory, sleep patterns, nociception, and hormone
secretion (Ng et al., 2011). Over time, a variety of GABA
site agonists, such as CACA (cis-4-aminocrotonic acid;
Fig. 39C), (+)-CAMP [(+)-cis-2-aminomethylcyclopro-
pane carboxylic acid; Fig. 39C] or cis-3-ACPBuPA (cis-
3-aminocyclopentanylbutyl-phosphinic acid; Fig. 39C),
and antagonists, such as TPMPA (1,2,5,6-tetrahydro-
pyridine-4-yl)methylphosphinic acid; Fig. 39C), were
identified that selectively activated and inhibited, re-
spectively, r-containingGABAA receptors comparedwith
heteromeric GABAA receptors or metabotropic GABAB
receptors (Chebib, 2004; Ng et al., 2011). In addition,
some ligands with unique pharmacological profiles have
been identified that show selectivity for one r subtype
over others (Ng et al., 2011; Naffaa et al., 2017).
VI. Discrepancy between the In Vivo Effects of
Drugs in Rodent and Human Studies
Subtype-selective drugs are important tools for in vitro
cell culture or brain slice studies to clarify a possible
contribution of a receptor subtype to the measured effect
or in preclinical studies for the investigation of the role of
receptor subtypes in the regulation of physiologic func-
tions. But the main motivation for the development of
such compounds is the hope to finally identify more
selective drugs with fewer side effects and especially,
anxiolytic drugs lacking sedation, hypnotic activity, and
ataxia. One of the main obstacles in the development of
such drugs, however, was recently addressed (Skolnick,
2012): compounds claimed to exhibit selectivity for a2/a3-
containing GABAA receptor subtypes, such as MRK 409 -
(Atack et al., 2011b) or TPA023B (Atack et al., 2011a), and
demonstrating a wide dose separation in their anxiolytic-
like and sedative effects in rodents, in human studies
exhibited actions more or less similar to those of the
classic benzodiazepines, eliciting tiredness, drowsiness,
and dizziness and at higher doses marked sedation in
addition to their anxiolytic effects (Skolnick, 2012). Al-
though the anxiolytic effects of TPA023 were significantly
superior to placebo in three separate Phase II studies on
generalized anxiety disorder without inducing sedation,
in a study with 12 healthy volunteers this compound
induced signs of sedation (including drowsiness and
dizziness) in some volunteers and elicited a reduced
saccadic peak velocity similar to a comparable dose
of lorazepam as a possible additional indicator of a
sedative action (de Haas et al., 2007; Skolnick, 2012).
On the contrary, compounds such as ocinaplon or alpidem,
whichwere not GABAA receptor subtype selective at all in
recombinant receptor studies, reportedly behaved as
anxiolytics with no sedative component in both rodents
andhumans (Musch et al., 1988; Lippa et al., 2005; Czobor
et al., 2010; Skolnick, 2012). Based on these apparently
paradoxical results, the concept of receptor subtype
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selectivity as a basis for generating drugs with reduced
side effects was seriously questioned, and the enthusi-
asm of the pharmaceutical industry for the development
of GABAA receptor subtype-selective drugs was dra-
matically reduced (Skolnick, 2012).
Given the discussion above, it is evident, however, that
none of the drugs currently available is truly receptor
subtype selective. By accepting the finding that even a
subtle modulation of a receptor subtype can influence
behavior, it has to be concluded that the effects of these
“selective” drugs cannot be attributed exclusively to the
receptor for which they possess the highest affinity or
efficacy. In addition, evidence is accumulating that not
only a2-containing receptor subtypes, but also a5- (Botta
et al., 2015; Behlke et al., 2016)- or a4- and d-containing
receptor subtypes (Marowsky and Vogt, 2014) contribute
to the modulation of anxiety. The anxiolytic but reduced
sedative effects of the a2/a3-selective drugs in rodents
might thus have been caused by an optimally balanced
modulation of various receptor subtypes involved in the
regulation of anxiety and sedation in these species. The
comparable anxiolytic but relatively increased sedative
properties of these drugs in humans could then suggest
thatGABAA receptor subtypesmodulating anxietymight
be similar, but receptors mediating sedation might be
different in rodents and man (Skolnick, 2012).
The validity of animal models used in anxiety and
depression research is not universally accepted. Espe-
cially scientists in the field of neurodevelopmental and
psychiatric disorders often indicate that nonhuman
animals can never express the full range of abilities
and disabilities that characterize humans (Garner
et al., 2009; Blanchard et al., 2013). While this may
be and probably is true, it does not compromise the
translational validity of at least some animal models
used in anxiety studies. In recent years, fear condi-
tioning models from non-human animal research have
been substantiated and extended in humans, using
neuropsychological and neuroimaging methodologies
(Delgado et al., 2006). Recently, the open field test has
been demonstrated to be related to human agoraphobic
fear (Walz et al., 2016).
In addition, it is generally accepted that biology is
similar in different mammalian species, although the
complexity of their brains and the exact regulation of
individual functions might be different. Apparently, the
discrepancy in the behavioral effects of GABAA recep-
tor subtype-preferring drugs in rodents and humans
is observed rather in their sedative than anxiolytic-
like effects, although animal models of sedation are
much less disputed than those of anxiety research. It
is thus more probable that additional neuronal sys-
tems are involved in the regulation of tiredness, drows-
iness, dizziness, and sedation in the more complex and
better controlled human brain, thus increasing the
overall inhibition by the drugs applied. This possibility
is supported by evidence indicating that the regional
distribution of GABAA receptor subunits is at least
partially different in rodent and human brains
(Waldvogel et al., 1999; Loup et al., 2000; Stojanovic
et al., 2016; Stefanits et al., 2018). In addition, it has
been demonstrated that a1bg2 receptors are expressed
in human (Hellsten et al., 2010), but not reliably in
rodent, noradrenergic locus coeruleus neurons (Luque
et al., 1994; Chen et al., 1999). Since locus coeruleus
neurons are involved in regulation of vigilance states,
species differences in the expression profile of a1bg2
receptors in these neurons might thus contribute to the
increased sedative effects of a2/a3 preferring benzodi-
azepine site ligands in humans, if these compounds also
exert a certain degree of activity at a1 receptors
(Hellsten et al., 2010). A positive modulation of a5
receptors (Savic et al., 2008b) or a3 receptors (Behlke
et al., 2016) might also contribute to sedation. En-
hanced expression of such receptors in humans might
thus also contribute to the enhanced adverse effects of
insufficiently selective GABAA receptor ligands. There-
fore, compounds that are really receptor subtype selec-
tive and that completely avoid the majority of receptors
mediating sedation, might dramatically improve the
situation and increase the separation between their
anxiolytic and sedative action also in the human brain.
A. Receptors Containing b1-Subunits Might
Contribute to the Sedative Action of Benzodiazepine
Site Ligands
It is generally assumed that the type of b subunit in a
receptor subtype does not significantly influence the
action of benzodiazepine site ligands (Hadingham et al.,
1993). However, this does not hold true for all benzodi-
azepine site ligands (Sieghart, 1995; Stevenson et al.,
1995; Gee et al., 2010; Varagic et al., 2013a). A possible
involvement of b1 subunit-containing GABAA receptors
in the regulation of wakefulness was suggested by the
use of the b1-preferring fragrant dioxane derivatives
(section V.I.2) (Sergeeva et al., 2010). The importance of
a1b1g2 GABAA receptors for eliciting ataxia, sedation,
and sleep was then further emphasized by studies using
b2/3-selective enaminones (Gee et al., 2010) (sectionV.J.3).
These compounds allosterically modulate GABAA
receptors via a so far unidentified binding site and
compared with other b2/3 selective compounds, such as
loreclezole, tracazolate, or etomidate, exert a dramatically
reducedmaximal efficacy at a1b1g2 over a1b2g2 GABAA
receptors (Gee et al., 2010). These enaminones produced
anxiolytic-like actions with reduced ataxic or sleep-
inducing effects (Gee et al., 2010; Yanovsky et al., 2012)
and also reduced abuse liability or memory impairment
(Yanovsky et al., 2012; Yoshimura et al., 2014).
The activity of loreclezole and other b2/3-selective
compounds at b1-containing receptors might have been
still too high (Gee et al., 2010) to avoid sedative side
effects. In addition, b2- or b3-containing receptors
might also contribute to the sedative actions of these
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compounds (Belelli et al., 2005; Groves et al., 2006).
Nevertheless, the extent of modulation of a1b1g2
receptors might have contributed to the extent of the
sedative and ataxic effects of the currently available
drugs. Ocinaplon exhibits a lowermodulation of a1b1g2
receptors than bretazenil or diazepam (Gee et al., 2010).
It might thus be interesting to investigate whether the
sedative and ataxic effects of ocinaplon, MRK 409, TPA
023, and TPA 023B or of any other drug for which
preclinical as well as clinical data are available, corre-
late with their efficacy at b1-containing GABAA
receptors.
GABAA receptors containing b1 subunits are expressed
in the brain stem and arousal-related areas of the rat
brain, for instance in the reticular thalamic nucleus,
which is an important area for modulating sleep (Pirker
et al., 2000; Gee et al., 2010). They are relatively minor
receptor subtypes compared with those containing b2 or
b3 subunits. Depending on the brain region investigated,
about 20%–30%, 65%, or 55% of all GABAA receptors
contain b1, b2 or b3 subunits, respectively (Sieghart and
Sperk, 2002). The finding that these percentages add up
to .100% indicates a significant colocalization of b1, b2,
or b3 subunits in GABAA receptors (Jechlinger et al.,
1998). A possible contribution of a minor GABAA receptor
subtype to the sedative effects of MRK 409 in humans
was suggested by the extremely low receptor occupancy
(,10%) of this compound under conditions that caused
sedation in young healthy male volunteers (Atack et al.,
2011b). Thismight have been caused by an especially high
potency or efficacy of this compound for a low abundance
receptor subtype mediating sedation in man. To investi-
gate a possible contribution of b1-containing receptors to
the sedative effects of MRK 409 and to possibly identify
the GABAA receptor subtype involved, the effects of MRK
409 at recombinant GABAA receptors composed of a1–
6b1g123 should be investigated and compared with the
respective receptors containing b2 or b3 subunits.
B. Receptors Containing g1 or g3 Subunits, or Those
Containing a4, a6, or d Subunits, Might Contribute to
the In Vivo Effects of Benzodiazepine Site Ligands
Benzodiazepine site ligands not only interact with
GABAA receptors containing g2 subunits, but also with
those containing g1 (Puia et al., 1991; Wafford et al.,
1993; Sieghart, 1995; Khom et al., 2006) or g3 subunits
(Herb et al., 1992; Sieghart, 1995; Davies et al., 2000;
Lippa et al., 2005). But so far, a possible contribution of
such receptors to the spectrum of in vivo actions of
benzodiazepine site ligands was not considered and no
compounds have been identified that selectively modu-
late g1 or g3 receptors. Although g1 or g3 receptors are
much less abundant in themammalian brain than those
containing g2 subunits (Pirker et al., 2000; Sieghart and
Sperk, 2002), they might have important regulatory
functions. The presence of g1 receptors in the amygdala
(Pirker et al., 2000; Esmaeili et al., 2009) might suggest
their possible involvement in the regulation of anxiety,
and ligands interacting with such receptors might
mediate some of their effects via this mechanism and
this could enhance their anxiolytic relative to their
sedative effects.
Imidazobenzodiazepines (Figs. 5, 25–29, 31–33),
pyrazoloquinolinones (Fig. 34), b-carbolines, such as
DMCM (Fig. 38) and other structural classes of benzo-
diazepine site ligands, not only modulate the diazepam-
sensitive a1,a2,a3,a5bg2 receptors, but also a4 and a6
subunit containing GABAA receptors (Sieghart, 1995;
Stevenson et al., 1995; Ramerstorfer et al., 2010;
Varagic et al., 2013a), and thus effects mediated by
these drugs via these receptor subtypes cannot be ignored.
The recent identification of a pyrazoloquinolinone mod-
ulating a1b3d, a4b3d, and a6b3d receptors (Mirheydari
et al., 2014) together with the observation that extra-
synaptic receptors containing a4 and d subunits seem to
be involved in inducing sedation and sleep (Belelli and
Lambert, 2005; Belelli et al., 2005) and possibly also
anxiety (Marowsky and Vogt, 2014) indicate that modu-
lation of such receptors can contribute to the overall
action of such compounds. A possible modulation of such
receptors cannot be excluded before appropriate exper-
iments have been performed.
C. Additional Interaction with Targets Different from
GABAA Receptors Could Also Contribute to the
Separation of Anxiolytic and Sedative Properties
of Ligands
Alpidem, similar to the structurally related zolpidem,
potently and efficiently modulates a1-, a2-, and a3-
containing receptors, and exhibits no effects at a5
receptors (Puia et al., 1991; Costa and Guidotti, 1996).
Whereas alpidem has anxiolytic but low sedative ef-
fects, zolpidem is a sedative hypnotic drug in humans.
Both of these drugs, however, exhibit a similar modu-
latory effect at GABAA receptors containing b1 subunits
(Puia et al., 1991; Costa and Guidotti, 1996). But in
contrast to zolpidem, alpidem also has a high affinity for
TSPO, which seems to be involved in the regulation of
neurosteroid synthesis and is also discussed as a target
for anxiolytic drugs (Costa et al., 2012;Nothdurfter et al.,
2012). Similarly, the anxioselective pyrazolopyridine
CGS 20625 not only acts via GABAA receptors but
additionally exhibits some interaction with TSPO,
known previously as the “peripheral benzodiazepine
receptor” (Williams et al., 1989). Therefore, the wider
separation of the anxiolytic over the sedative action of
CGS 20625 or of alpidem compared with zolpidem,
might have been caused by an additional interaction
of CGS 20625 or alpidem with TSPO.
D. A Low Potency and Efficacy of Compounds Might
Enhance Their Receptor Subtype-selective Actions
But how can ocinaplon act as a selective anxiolytic in
rodents and humans (Czobor et al., 2010), although it
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seems not to be receptor subtype selective at all (Lippa
et al., 2005; Berezhnoy et al., 2008)? Ocinaplon is a low
potency and low efficacy allosteric modulator. This is in
contrast to the previously investigated high potency,
low efficacy allostericmodulators such as bretazenil and
abecarnil (Ramerstorfer et al., 2010), MRK 409 (Fig. 12;
section V.D.5), TPA023 (Fig. 11; section V.D.4), or
TPA023B (Fig. 7; section V.C.2), which lost their
anxioselective action observed in rodents when applied
in humans (Skolnick, 2012). Due to their high potency,
the latter drugs probably achieved brain concentrations
eliciting their maximal efficacy at all receptor subtypes
under conditions of in vivo application and by that
sufficiently activated also those receptors mediating
sedation in humans. The potency of ocinaplon for
modulating GABAA receptors, however, is about 100–
1000-fold lower than that of diazepam, depending on
the receptor subtype investigated, and in addition this
compound exhibits lower efficacy (Berezhnoy et al.,
2008). This indicates that an at least 100–1000-fold
higher concentration of ocinaplon has to be reached at
GABAA receptors to elicit a modulation similar to that
of diazepam. It is quite possible that concentrations
sufficient to modulate GABAA receptors mediating
sedation cannot be achieved by this drug.
Therefore, the low potency and low efficacy of ocina-
plon, possibly combined with an intrinsic inability to
sufficiently interact with those receptor subtypes medi-
ating sedation at the concentrations achieved, might
have added up to the favorable profile of this compound
in humans. If more compounds with low potency and low
efficacy, but with receptor subtype selectivity, such as
6-hydroxyflavone (Fig. 15; section V.D.8 (Ren et al.,
2010), baicalin (Fig. 14; section V.D.7) (Wang et al.,
2008), AZD7325 (Fig. 17; section V.D.10) (Christian
et al., 2015), PZ-II-029 (Fig. 34; section V.G.3) (Varagic
et al., 2013a), LAU159 (Treven et al., 2018), ELB138
(imepitoin), or ELB139 (Rabe et al., 2007; Rundfeldt and
Löscher, 2014), confirm this hypothesis in clinical inves-
tigations by demonstrating a wider separation of anxio-
lytic and sedative properties in humans, pharmaceutical
companies might have to radically change their strategy
for the development of more selective drugs: Instead of
developing high potency, high efficacy drugs with re-
ceptor subtype selectivity, the development of low po-
tency, low efficacy drugswith receptor subtype selectivity
might be more promising for eliciting selective actions.
Since drug efficacy plays a critical role in determining
the degree of GABAA receptor uncoupling, and, perhaps
in the development of tolerance and dependence (Primus
et al., 1996), low efficacy drugs might have an added
benefit in a long-term treatment of patients.
VII. Outlook
Given the data summarized above, it is evident that
many of the compounds claimed to be selective for a
specific a1-, a2-, a3-, or a5b3g2 receptor subtypes are
only marginally selective and that their limited selec-
tivity is even further reduced by their high potency.
Generating compounds with reduced potency and effi-
cacy but high receptor subtype-selectivity seems to be a
way out of this problem. Such compounds, in addition to
their receptor subtype selectivity, might not achieve
concentrations in the brain that sufficiently modulate
receptor subtypes mediating sedative effects. Investigat-
ing such compounds in a clinical setting is also the only
possibility to clarify whether it is their high receptor
subtype selectivity that results in high functional selec-
tivity or whether functional selectivity is achieved by an
optimal balance of activity at various receptor subtypes.
In addition, the “receptor subtype selectivity” of ben-
zodiazepine site ligands so far was predominantly in-
vestigated at the “diazepam-sensitive” a1b3g2, a2b3g2,
a3b3g2, and a5b3g2 receptors only, although most if not
all of these drugs additionally can modulate receptors
containing the same a, but different b or g, subunits. All
these receptors exhibit a distinct regional, cellular, and
subcellular distribution in the brain and can be assumed
to exhibit distinct behavioral effects, but the investigation
of their function so far has been neglected. The same
holds true for receptors containing a4 or a6 subunits.
Certain structural classes of benzodiazepine site ligands
can also modulate these or even d-containing receptors.
Therefore, all of these receptor subtypes have to be
considered and investigated when claiming a “receptor
subtype selectivity” of a drug. Additional interaction
with such so far not investigated receptors can shift the
balance between anxiolytic and sedative effects. Al-
though an investigation of all these additional receptor
subtypes seems to be a tremendous task, it seems to
be feasible using high-throughput electrophysiological
measurements (Trumbull et al., 2003) or fluorometric
imaging plate readers (FLIPR) using membrane poten-
tial red dye, which redistributes across the plasma
membrane in a voltage-dependent manner (Nik et al.,
2017). In addition, the already available compounds
with limited receptor subtype selectivity and their
congeners, together with structural models of individual
GABAA receptor subtypes (Miller and Aricescu, 2014),
receptor subtype-specific pharmacophoremodels (Clayton
et al., 2007, 2015), and structure-based drug design
(Richter et al., 2012), will facilitate the development of
new and more selective drugs. Recent binding site
mapping in models of GABAA receptors has identified
additional binding sites in these receptors that possibly
also can be exploited for the development of receptor
subtype-selective drugs (Ernst and Sieghart, 2015;
Puthenkalam et al., 2016).
Finally, to strengthen the conclusions from biologic
datasets generated by available compounds with limited
or unclear receptor subtype selectivity, compounds from
the same structural class exhibiting a similar as well as
dissimilar selectivity profile together with compounds
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selectively antagonizing the actions of the investigated
drug at the receptor supposedly mediating its in vivo
action, should be included into the protocol. In addition,
positive controls (compounds from a different structural
class that are also active at the respective receptor
subtype) or negative controls (compounds exhibiting no
activity at the respective receptor subtype) should also be
included into the protocol, if available. The present
review can serve as a guide for the selection of adequate
positive or negative controls. Furthermore, the data
obtained with compounds preferentially interacting with
a certain receptor subtype have to be carefully inter-
preted by considering all the known interactions of the
compound at the drug concentrations achieved in the
brain. After all, a possible additional modulation by
the drug of other GABAA receptor subtypes or binding
sites or of different transmitter systems has to be
acknowledged in the discussion of the data.
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